ML12128A198: Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
(Created page by program invented by StriderTol)
Line 1: Line 1:
{{Adams
#REDIRECT [[CP-201200347, Transmittal of Year 2011 Radioactive Effluent Release Report]]
| number = ML12128A198
| issue date = 04/30/2012
| title = Enclosure 2 to TXX-12061, Comanche Peak Nuclear Power Plant Offsite Dose Calculation Manual (ODCM) Unit 1 and 2, Revision 31 and Revision 32
| author name =
| author affiliation = Luminant Generation Co, LLC, Luminant Power
| addressee name =
| addressee affiliation = NRC/NRR
| docket = 05000445, 05000446
| license number =
| contact person =
| case reference number = CP-201200347, TXX-12061
| document type = Calculation, Manual
| page count = 42
}}
 
=Text=
{{#Wiki_filter:Enclosure 2 to TXX-12061 Comanche Peak Nuclear Power Plant Offsite Dose Calculation Manual (ODCM)Unit 1 and 2, Revision 31 and Revision 32 REFERENCES
: 1. Boegli, J.S., R. R. Bellamy, W. L. Britz, and R. L. Waterfield, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants," NUREG-0133 (October 1978).2. Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10CFR Part 50, Appendix I, U. S. NRC Regulatory Guide 1.109, Rev. 1 (October 1977).3. "Environmental Report," TU Electric, Comanche Peak Steam Electric Station.4. "Final Safety Analysis Report," TU Electric, Comanche Peak Steam Electric Station.5. Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors, U.S. NRC Regulatory Guide 1.111 (March 1976).6. Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Release from Light-Water-Cooled Reactors, U.S. NRC Regulatory Guide 1.111, Rev. 1 (July 1977).7. Meteorology and Atomic Energy; Edited by Slade, D. H.; U. S. Department of Commerce (July 1968).8. "Technical Specifications," TU Electric, Comanche Peak Steam Electric Station.9. Implementation of Programmatic Controls for Radiological Effluent Technical Specifications in the Administrative Controls Section of the Technical Specifications and the Relocation of Procedural Details of RETS to the Offsite Dose Calculation Manual or to the Process Control Program (Generic Letter 89-01), USNRC, January 31, 1989.10. CPSES Technical Evaluation No. RP-90-3077, "Calculation of Site Related Ingestion Dose Commitment Factors For Sb-122." 11. "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," USNRC Regulatory Guide 1.109 (March 1976).12. Code of Federal Regulation, Title 10, Parts 20, 50, and 72.CPSES -UNITS 1 AND 2- ODCM X Rev. 31 3/4.11 RADIOACTIVE EFFLUENTS 3/4.11.4 TOTAL DOSE CONTROLS 3.11.4 In accordance with CPSES TS 5.5.4.j, the annual (calendar year) dose or dose commitment to any MEMBER OF THE PUBLIC due to releases of radioactivity and to radiation from uranium fuel cycle sources shall be limited to les's than or equal to 25 mrems to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrems.APPLICABILITY:
At all times.ACTION: a. With the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding twice the limits of Controls 3.11.1.2a., 3.11.1.2b, 3.11.2.2a, 3.11.2.2b, 3.11.2.3a., or 3.11.2.3b., calculations shall be made including direct radiation contributions from the units, the Independent Spent Fuel Storage Installation (ISFSI), and from outside storage tanks to determine whether the above limits of Control 3.11.4 have been exceeded.
If such is the case, prepare and submit a report to the NRC within 30 days, pursuant to 10 CFR 20.1301(d) and 10 CFR 20.2203(a)(4) that defines the corrective action to be taken to reduce subsequent releases to prevent recurrence of exceeding the above limits and includes the schedule for achieving conformance with the above limits. This report, as defined in 10 CFR 20.2203(b), shall include an analysis that estimates the radiation exposure (dose) to a MEMBER OF THE PUBLIC from uranium fuel cycle sources, including all effluent pathways and direct radiation, for the calendar year that includes the release(s) covered by this report. It shall also describe levels of radiation and concentration of radioactive material involved, and the cause of the exposure levels or concentrations.
If the estimated dose(s)exceeds the above limits, and if the release condition resulting in violation of 40 CFR Part 190 has not already been corrected, the report shall include a request for a variance in accordance with the provisions of 40 CFR Part 190. Submittal of the report is considered a timely request, and a variance is granted until staff action on the request is complete.SURVEILLANCE REQUIREMENTS 4.11.4.1 Cumulative dose contributions from liquid and gaseous effluents shall be determined in accordance with Controls 4.11.1.2, 4.11.2.2, and 4.11.2.3, and in accordance with the methodology and parameters in Part II of the ODCM.4.11.4.2 Cumulative dose contributions from direct radiation from the units, the ISFSI, and from radwaste storage tanks shall be determined in accordance with the methodology and parameters in Part II of the ODCM. This requirement is applicable only under conditions set forth in ACTION a. of Control 3.11.4.CPSES -UNITS 1 AND 2- ODCM PART I13/4-34 Rev. 31 3/4.11 RADIOACTIVE EFFLUENTS BASES 3/4.11.4 TOTAL DOSE This control is provided to meet the dose limitations of 40 CFR Part 190 that have been incorporated into 10 CFR Part 20.1301(e).
The control requires the preparation and submittal of a report whenever the calculated doses due to releases of radioactivity and to radiation from uranium fuel cycle sources exceed 25 mrems to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrems. For sites containing up to four reactors, it is highly unlikely that the resultant dose to a MEMBER OF THE PUBLIC will exceed the dose limits of 40 CFR Part 190 if the individual reactors remain within twice the dose design objectives of Appendix I, and if direct radiation doses from the units (including outside storage tanks, etc.)are kept small. The report will describe a course of action that should result in the limitation of the annual dose to a MEMBER OF THE PUBLIC to within the 40 CFR Part 190 limits. For the purposes of the report, it may be assumed that the dose commitment to the MEMBER OF THE PUBLIC from other uranium fuel cycle sources is negligible, with the exception that dose contributions from other nuclear fuel cycle facilities at the same site or within a radius of 8 km must be considered.
If the dose to any MEMBER OF THE PUBLIC is estimated to exceed the requirements of 40 CFR Part 190, the report with a request for a variance (provided the release conditions resulting in violation of 40 CFR Part 190 have not already been corrected), in accordance with the provisions of 40 CFR 190.11 and 10 CFR 20.2203(a)(4) and 20.2203(b), is considered to be a timely request and fulfills the requirements of 40 CFR Part 190 until NRC staff action is completed.
The variance only relates to the limits of 40 CFR Part 190, and does not apply in any way to the other requirements for dose limitation of 10 CFR Part 20, as addressed in Controls 3.11.1.1 and 3.11.2.1.
An individual is not considered a MEMBER OF THE PUBLIC during any period in which he/she is engaged in carrying out any operation that is part of the nuclear fuel cycle. Demonstration of compliance with the limits of 40 CFR Part 190 or with the design objectives of Appendix I to 10 CFR Part 50 will be considered to demonstrate compliance with the 0.1 rem limit of 10 CFR 20.1301.CPSES -UNITS 1 AND 2- ODCM PART I B 3/4-8 Rev. 31 3/4.12 RADIOLOGICAL ENVIRONMENTAL MONITORING BASES 3/4.12.1 MONITORING PROGRAM The Radiological Environmental Monitoring Program required by this control provides representative measurements of radiation and of radioactive materials in those exposure pathways and for those radionuclides that lead to the highest potential radiation exposure of MEMBERS OF THE PUBLIC resulting from the plant and ISFSI operation.
This monitoring program implements Section IV.B.2 of Appendix I to 10 CFR Part 50 and thereby supplements the Radiological Effluent Monitoring Program by verifying that the measurable concentrations of radioactive materials and levels of radiation are not higher than expected on the basis of the effluent measurements and the modeling of the environmental exposure pathways.
Guidance for this monitoring program is provided by the Radiological Assessment Branch Technical Position on Environmental Monitoring, Revision 1, November 1979. The initially specified monitoring program will be effective for at least the first 3 years of commercial operation.
Following this period, program changes may be initiated based on operational experience.
The required detection capabilities for environmental sample analyses are tabulated in terms of the lower limits of detection (LLDs). The LLDs required by Table 4.12-1 are considered optimum for routine environmental measurements in industrial laboratories.
It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an a posteriori (after the fact) limit for a particular measurement.
Detailed discussion of the LLD, and other detection limits, can be found in Currie, L. A., "Lower Limit of Detection:
Definition and Elaboration of a Proposed Position for Radiological Effluent and Environmental Measurements," NUREG/CR-4007 (September 1984), and in the HASL Procedures Manual, HASL-300.3/4.12.2 LAND USE CENSUS This control is provided to ensure that changes in the use of areas at or beyond the SITE BOUNDARY are identified and that modifications to the Radiological Environmental Monitoring Program are made if required by the results of this census. The best information from the door-to-door survey, from aerial survey or from consulting with local agricultural authorities shall be used. This census satisfies the requirements of Section IV.B.3 of Appendix I to 10 CFR Part 50. Restricting the census to gardens of greater than 50 m 2 provides assurance that significant exposure pathways via leafy vegetables will be identified and monitored since a garden of this size is the minimum required to produce the quantity (26 kg/year) of leafy vegetables assumed in Regulatory Guide 1.109 for consumption by a child. To determine this minimum garden size, the following assumptions were made: (1) 20% of the garden was used for growing broad leaf vegetation (i.e., similar to lettuce and cabbage), and (2) a vegetation yield of 2 kg/m 2.3/4.12.3 INTERLABORATORY COMPARISON PROGRAM The requirement for participation in an approved Interlaboratory Comparison Program is provided to ensure that independent checks on the precision and accuracy of the measurements of radioactive materials in environmental sample matrices are performed as part of the quality CPSES -UNITS 1 AND 2- ODCM PART I B 3/4-9 Rev. 31 ADMINISTRATIVE CONTROLS RADIOACTIVE EFFLUENT RELEASE REPORT (Continued)
The Radioactive Effluent Release Report shall include a list and description of unplanned releases, from the site to CONTROLLED AREAS and UNRESTRICTED AREAS, of radioactive materials in gaseous and liquid effluents made during the reporting period.The Radioactive Effluent Release Report shall include a listing of new locations for dose calculations and/or environmental monitoring identified by the Land Use Census pursuant to Control 3.12.2.The Radioactive Effluent Release Report shall also include the following:
an explanation as to why the inoperability of liquid or gaseous effluent monitoring instrumentation was not corrected within the time specified in Controls 3.3.3.4 or 3.3.3.5, respectively; and a description of the events leading to liquid holdup tanks or gas storage tanks exceeding the Technical Specification limits.6.14 OFFSITE DOSE CALCULATION MANUAL (ODCM)Changes to the ODCM: a. Shall be documented and records of reviews performed shall be retained as required FSAR Section 17.2.17.1.
This documentation shall contain: 1) Sufficient information to support the change together with the appropriate analyses or evaluations justifying the change(s) and 2) A determination that the change will maintain the level of radioactive effluent control required by 10 CFR 20.1302, 40 CFR Part 190, 10 CFR 72.104, 10 CFR 50.36a, and Appendix I to 10 CFR Part 50 and not adversely impact the accuracy or reliability of effluent, dose, or setpoint calculations.
: b. Shall become effective after review and acceptance by the SORC and the approval of the Vice President of Nuclear Operations.
: c. Shall be submitted to the Commission in the form of a complete, legible copy of the entire ODCM as a part of or concurrent with the Radioactive Effluent Release Report for the period of the report in which any change to the ODCM was made.Each change shall be identified by markings in the margin of the affected pages, clearly indicating the area of the page that was changed, and shall indicate the date (e.g., month/year) the change was implemented.
CPSES -UNITS 1 AND 2- ODCM PART I16-3 Rev. 31 TABLE OF CONTENTS (continued)
Number/Title Paqe 1.2.4 Auxiliary Building to LVW Pond 111-8 Radiation Monitor (XRE-5251A) 1.3 Dose Calculations for Liquid Effluents 111-8 1.3.1 Calculation of Dose Due to 111-9 Liquid Releases 1.3.2 Calculation of Dose Due to 11 1-10 Radionuclide Buildup in the Lake 1.4 Dose Projections for Liquid Effluents 11 1-12 1.5 Definitions of Common Liquid Effluent 111-12 Parameters 2.0 GASEOUS EFFLUENTS 112-1 2.1 Radiological Effluent Control II 2-2 3/4.11.2.1 Compliance 2.1.1 Dose Rates Due to Noble Gases II 2-2 2.1.2 Dose Rates Due to Radioiodines, II 2-4 Tritium, and Particulates 2.2 Gaseous Effluent Monitor Setpoints II 2-4 2.2.1 Plant Vent Effluent Release Rate 112-5 Monitors (XRE-5570A/XRE-5570B)
Effluent Release Rate Channels 2.2.2 Plant Vent Stack Noble Gas Activity II 2-6 Monitors (XRE-5570A/XRE-5570B and XRE-5567A/XRE-5567B) 2.2.3 Sampler Flow Rate Monitors II 2-6 (X-RFT-5570A-1
/X-RFT-5570B-1) 2.2.4 Auxiliary Building Ventilation.
II 2-6 Exhaust Monitor (XRE-5701) 2.2.5 Containment Atmosphere Gaseous II 2-7 Monitors (1 RE-5503/2RE-5503) 2.3 Dose Calculations for Gaseous Effluents 112-8 2.3.1 Dose Due to Noble Gases 112-8 2.3.2 Dose Due to Radioiodines, Tritium, C-14, II 2-9 and Particulates 2.4 Dose Projections for Gaseous Effluents II 2-11 2.5 Dose Calculations to Support Other II 2-11 Requirements CPSES -UNITS 1 AND 2- ODCM iii Rev. 32
= Flow rate from each release source v (cm 3/sec)Qiv = Release rate of radionuclide i from release source v (uCi/sec)v = Index over all release sources 2.1.2 Dose Rates Due to Radioiodines, Tritium, and Particulates Organ dose rates due to iodine-131 and iodine-133, tritium, and all radioactive materials in particulate form with half-lives greater than eight days released from the site will be calculated to implement the requirements of Radiological Effluent Control 3/4.11.2.1 .b as follows: Do Dov (X/Q) E PAQi [Eq. 2-4]v v IP&T Where: Do = Total organ dose rate due to iodine-131, iodine-133, particulates with half-lives greater than eight days, and tritium from all release sources. (mrem/yr)Dov Organ dose rate due to iodine-1 31, iodine-1 33, particulates with half-lives greater than eight days, and tritium from release source v. (mrem/yr)Pi Pathway dose rate parameter factor for radionuclide, i, (for radioiodines, particulates, and tritium) for the inhalation pathway in mRem/yr per uCi/m 3 (Table 2.3). The methodology used for determining values of Pi is given in Appendix A.IP&T = Iodine-1 31, iodine-1 33, particulates with half-lives greater than eight days, .and tritium. These are the isotopes over which the summation function is to be performed.
All other variables are previously defined.2.2 GASEOUS EFFLUENT MONITOR SETPOINTS The gaseous monitor setpoint values, as determined using the methodology in the following sections, will be regarded as upper bounds for the actual setpoint adjustments.
Setpoints may be established at values lower than the calculated values if desired.Further, if the calculated value should exceed the maximum range of the monitor, the setpoint shall be adjusted to a value that falls within the normal operating range of the monitor.If a calculated setpoint is less than the measured concentration associated with the particular release pathway, no release may be made. Under such circumstances, contributing source terms shall be reduced and the setpoint recalculated.
CPSES -UNITS 1 AND 2- ODCM PART II12-4 Rev. 32 Where: 3.17 x 10-8 = Fraction of a year represented by one second.Q'i = Cumulative release of radionuclide i during the period of interest from all release sources. (uCi)(Q'i = Qi (uCi/sec) x release duration (sec))Q'i is based on the noble gas activities in each plant vent stack and WGDT or Containment Samples required by Radiological Effluent Control 3/4.11.2.1, Table 4.11-2.All other variables are previously defined.b. Air Dose Due to Beta Emissions Do Air dose due to beta emissions from noble gas radionuclides. (mrad)= 3.17x1-8 (X/Q) NiQ ' [Eq. 2-14](noble gases)Where: Ni Air dose factor due to beta emissions from noble gas radionuclide i from Table 2.2.(mRad/yr per uCi/m 3).All other variables are previously defined.NOTE: If the methodology in this section is used in determining dose to an individual rather than air dose due to noble gases, substitute Ki for Mi, (Li + 1.1 Mi) for Ni, and the Annual Average X/Q values from information listed and maintained current in the results of the annual Land Use Census for the highest annual average relative concentration (X/Q) at the SITE BOUNDARY.2.3.2 Dose Due to Radiodines, Tritium, C-14, and Particulates For implementation of Radiological Effluent Control 3/4.11.2.3, the cumulative dose to each organ of an individual due to iodine-131, iodine-133, tritium, C-14, and particulates with half-lives greater than 8 days will be calculated at least once per 31 days and a cumulative summation of these doses will be maintained for each calendar quarter and each calendar year. The dose over the desired period will be calculated as follows: Dp= E 3.17x10-8 W' Z Rp i,a,o Q! [Eq. 2-15]Paths I&PT CPSES- UNITS 1 AND 2- ODCM PART II12-9 Rev. 32 Where: Dp Dose due to all real pathways to organ, o, of an individual in age group, a, from iodine-1 31, iodine-1 33, tritium, and radionuclides in particulate form with half-lives greater than eight days from all release sources (mRem).W = Dispersion parameter for estimating the dose to an individual at the location where the combination of existing pathways and receptor age groups indicates the maximum potential exposures.
Locations of interest are listed in the results of the annual Land Use Census, W' X/Q for the inhalation pathway in sec/m 3.X/Q is the annual average relative concentration at the location of interest.Values for X/Q are listed in the results of the annual Land Use Census. If desired, the highest individual receptor X/Q or X/Q value may be used, or W = D/Q for the food and ground plane pathways in m-2.D/Q is the annual average deposition at the location of interest.
Values for D/Q are listed in the results of the annual Land Use Census. If desired, the highest individual receptor D/Q or D/Q value may be used.NOTE: For tritium and C-14, the dispersion parameter, W' is taken as the annual average X/Q values from information listed and maintained current in the results of the annual Land Use Census for inhalation, food and ground plane pathways.RPi,a,o Dose factor for radionuclide i, pathway p, age group a and organ o, in mRem/yr per uCi/m 3 for the inhalation pathway and m 2 (mRem/yr) per uCi/sec for food and ground plane pathways, except for tritium which is in mRem/yr per uCi/m 3 for all pathways.
The values for RPi,a,o for each pathway, radionuclide, age group and organ are listed in Table 2.4.The methodioogies used for determining values of RPi,a,o for each pathway are given in Appendices B through F.Qi Cumulative release of radionuclide, i, during the period of interest (uCi). Q'i is based on the activities measured in each plant vent stack from the analyses of the particulate and iodine samples required by Radiological Effluent Control 3/4.11.2.1, Table 4.11-2. Carbon-14 (C14) airborne activity released to the environment is established based on actual power generation as discussed in Regulatory Guide 1.21, Revision 2. The methodology for estimating C-14 produced and released to the environment via gaseous effluents from CPNPP is provided in"Estimation of Carbon-14 in Nuclear Power Plant Gaseous Effluents", EPRI, Palo Alto, CA: 2010. 1021106.CPSES -UNITS 1 AND 2- ODCM PART II12-10 Rev. 32 I&PT lodines, particulates with half-lives greater than eight days, and tritium. These are the isotopes over which the summation function is to be performed.
PATHS The real pathways of exposure to individuals at the locations of interest.2.4 DOSE PROJECTIONS FOR GASEOUS EFFLUENTS Radiological Effluent Control 3/4.11.2.4 requires that appropriate portions of the PRIMARY PLANT VENTILATION SYSTEM and WASTE GAS HOLDUP SYSTEM be used to reduce releases of radioactivity when the projected doses due to the gaseous effluent from a unit to areas at or beyond the SITE BOUNDARY would exceed, in a 31-day period, either: 0.2 mrad to air from gamma radiation; or 0.4 mrad to air from beta radiation; or 0.3 mrem to any organ of a MEMBER OF THE PUBLIC.The following calculational method is provided for performing this dose projection:
At least once every 31 days the gamma air dose, beta air dose and the maximum organ dose for each unit for the previous three months will be divided by the number of days in the three month period and multiplied by 31. Also, this dose projection may include the estimated dose due to any anticipated unusual releases during the period for which the projection is made, such as Waste Gas Decay Tank release. If the projected doses for a unit exceed any of the values listed above, appropriate portions of the PRIMARY PLANT VENTILATION SYSTEM and WASTE GAS HOLDUP SYSTEM shall be used to reduce radioactivity levels prior to release.2.5 DOSE CALCULATIONS TO SUPPORT OTHER REQUIREMENTS For the purpose of implementing the requirements of Radiological Effluent Control 6.9.1.4, the Annual Radioactive Effluent Release Report shall include an assessment of the radiation doses due to radioactive liquid and gaseous effluents from the station during the previous year of operation.
This assessment shall be a summary of the doses determined in accordance with Section 1.3 for doses due to liquid effluents, Section 2.3.1 for air doses due to noble gases, and Section 2.3.2 for doses due to iodines, tritium, and particulates.
This same report shall also include an assessment of the radiation doses from radioactive liquid and gaseous effluents to members of the public due to their activities inside the SITE BOUNDARY.
This assessment shall be performed in accordance with the methodologies in Section 1.3, 2.3.1, and 2.3.2, using either historical average or concurrent dispersion and deposition parameters for the locations of interest, and taking into account occupancy factors. All assumptions and factors used in the determination shall be included in the report.For the purpose of implementing Radiological Effluent Control 3/4.12.2 dose calculations for the new locations identified in the land use census shall be performed using the methodology in Section 2.3.2, substituting the appropriate pathway receptor dose factors and dispersion parameters for the location(s) of interest.
Annual average dispersion CPSES -UNITS 1 AND 2- ODCM PART 1I12-11 Rev. 32 parameters may be used for these calculations.
If the land use census changes, the critical location (i.e., the location where an individual would be exposed to the highest dose) must be reevaluated for the nearest residence, the nearest milk animal, and the nearest vegetable garden. Additionally, when a location is identified that yields a calculated dose 20% greater than at a location where environmental samples are currently being obtained, add the new location within 30 days to the Radiological Environmental Monitoring locations described in Section 3.1 of this manual.For the purpose of implementing Radiological Effluent Control 3/4.11.4, the total annual dose to any member of the public due to releases of radioactivity and to radiation from uranium fuel cycle sources may be determined by summing the annual doses determined for a member of the public in accordance with the methodology of Sections 1.3, 2.3.1, and 2.3.2 and the direct radiation dose contributions from the units and from outside storage tanks to the particular member of the public. This assessment must be performed in the event calculated doses from the effluent releases exceed twice the limits of Controls 3/4.11.1.2, 3/4.11.2.2, or 3/4.11.2.3.
This assessment will be included in the Annual Radioactive Effluent Release Report to be submitted the year after the assessment was required.
Otherwise, no assessments are required.For the evaluation of doses to real individuals from liquid releases, the same calculation methods as employed in Section 1.3 will be used. However, more encompassing and realistic assumptions will be made concerning the dilution and ingestion of radionuclides.
The results of the Radiological Environmental Monitoring Program will be used in determining the realistic dose based on actual measured radionuclide concentrations.
For the evaluation of doses to real individuals from gaseous releases, the same calculational methods as employed in Sections 2.3.1 and 2.3.2 will be used. In Sections 2.3.1, the total body dose factor should be substituted for the gamma air dose factor (Mi) to determine the total body dose. Otherwise, the same calculational sequence applies. More realistic assumptions will be made concerning the actual location of real individuals, the meteorological conditions, and the consumption of food. Data obtained from the latest land use census should be used to determine locations for evaluating doses. The results of the Radiological Environmental Monitoring Program will be included in determining more realistic doses based on actual measured radionuclide concentrations.
The dose component due to direct radiation may be determined by calculation or actual measurement (e.g., OSL (Optically Stimulated Luminescence)
Badge, micro-R meter).The calculation or actual measurement of direct radiation shall be documented in the Special Report that must be submitted if this determination is required.2.6 METEOROLOGICAL MODEL 2.6.1 Dispersion Calculations Atmospheric dispersion for gaseous releases is calculated using a straight line flow Gaussian model similar to the Constant Mean Wind Direction model given in Regulatory Guide 1.111, Section C.1 .c. The method given here is modified by including factors to CPSES -UNITS 1 AND 2- ODCM PART II12-12 Rev. 32 account for plume depletion and effects of the open terrain. The average relative concentration is given by the following equation: X = 2.0325 Q Where: X/Q K y (IN r njk [Eq. 2-16]K Ark cnejk entrt= Average concentration normalized by source strength. (sec/m 3)2.032 = (2/n)1/2 * (2n/16)-1.5 = Plume depletion factor at distance r for the applicable stability class (Figure 2.2). Normally, a value of 1.0 is assumed when undepleted X/Q values are to be used in dose calculations.
K = Terrain correction factor (Figure 2.5).njk= Number of hours meteorological conditions are observed to be in a given wind direction, wind speed class, k, and atmospheric stability class, j.N = Total hours of valid meteorological data throughout the period of release.NOTE: If hourly meteorological data are used, all variable subscripts are dropped, njk and N are set equal to 1, and the hourly averaged meteorological variables are used in the model.r]jk Z j(r)Downwind distance from the release point to the location of interest. (meters)Average windspeed (midpoint of windspeed class, k) measured at the 10 meter level during stability class j. (meters/sec)
Vertical plume spread with a volumetric correction for a release within the building wake cavity, at a distance, r, for stability class, j, expressed in meters.NOTE: All parameters are considered dimensionless unless otherwise indicated.
The equation for calculating ,j(r) is: YXj(r) = the lesser of{1 (Y 2 +0.5 b2/TE)2[Eq. 2-17][Eq. 2-18]CPSES -UNITS 1 AND 2- ODCM PART II12-13 Rev. 32 Where: rj = Vertical standard deviation of materials in the plume at distance, r, for atmospheric stability class, j, expressed in meters (Figure 2.3).0.5 = Building shape factor.b = Vertical height of the reactor containment structure (79.4 meters).2.6.2 Deposition Calculations The relative deposition per unit area is calculated as follows: D K [Eq. 2-19]Q 0.3927 r Where: D/Q Deposition per unit area normalized by source strength (m-2)D9 Relative deposition rate for a ground level release (m-1)(Figure 2.4)z = Fraction of time the wind blows to the sector of interest.NOTE: If hourly meteorological data are used, z is set equal to one.0.3927 = Width in radians of a 22.50 sector.Other variables are as previously defined.NOTE: All parameters are considered dimensionless unless otherwise indicated.
2.7 DEFINITIONS OF GASEOUS EFFLUENTS PARAMETERS TERM DEFINITION AF Allocation Factor of 0.5 applied to account for releases from both stacks simultaneously.
This factor will limit the release rate contribution from each stack to 1/2 the limit for the site.B vertical height of the reactor containment structure.
CG the alarm setpoint for each plant vent stack noble gas activity monitor.(uCi/cm 3)Cf the alarm setpoint for each plant vent stack effluent release rate monitor.(uCi/sec)Caux the Auxiliary Building Ventilation Exhaust monitor alarm setpoint.(uCi/cm 3)Ccont the Containment Atmosphere Gaseous monitor alarm setpoint. (uCi/cm 3)CPSES -UNITS 1 AND 2- ODCM PART II12-14 Rev. 32 TERM DEFINITION Dg relative deposition rate for a ground-level release. (m-1)Do the total organ dose rate due to tritium, iodines, and particulates with half-lives greater than eight days from all gaseous release sources.(mRem/yr)Dov the organ dose rate due to tritium, iodines, and particulates with half-lives greater than eight days from gaseous release source v. (mRem/yr)Dp dose to any organ of an individual from radioiodines, tritium and radionuclides in particulate form with half-lives greater than eight days from all release sources. (mRem)Ds Skin dose rate at the SITE BOUNDARY due to noble gases from all release sources. (mRem/yr)DSV Skin dose rate at the SITE BOUNDARY due to noble gases from release source v. (mRem/yr)Dt Total body dose rate at the SITE BOUNDARY due to noble gases from all release sources. (mRem/yr)Dtv Total body dose rate at the SITE BOUNDARY due to noble gases from release source v. (mRem/yr)Do3 Air dose due to beta emissions from noble gases from all release sources. (mRad)Dy Air dose due to gamma emissions from noble gases from all release sources. (mRad)D/Q Annual average relative deposition at the location of interest. (m-2)6 Plume depletion factor at distance r for the appropriate stability class (radioiodines and particulates).
Fv Flow rate from each release source v. (cm 3/sec)Faux Maximum Auxiliary Building Ventilation flow rate (cm 3/sec) corresponding to 106,400 cfm.Fcont Maximum containment release flow rate (cm 3/sec) corresponding to 750 cfm for containment vents and 30,000 cfm for containment purges.Fpvs Maximum stack flow rate (cc/sec) corresponding to 115,000 cfm during normal operations and 130,000 cfm during containment purges.K terrain correction factor. (unitless)
Ki total body dose factor due to gamma emissions from noble gas radionuclide
: i. (mRem/yr per uCi/m 3)Li skin dose factor due to beta emissions from noble gas radionuclide i.(mRem/yr per uCi/m 3)Mi air dose factor due to gamma emissions from noble gas radionuclide i.(mrad/yr per uCi/m 3)CPSES -UNITS 1 AND 2- ODCM PART II12-15 Rev. 32 TERM DEFINITION Ni air dose factor due to beta emissions from noble gas radionuclide i.(mrad/yr per uCi/m 3)njk number of hours meteorological conditions are observed to be in a given wind direction, wind speed class k, and atmospheric stability class j.N total hours of valid meteorological data.Pi pathway dose rate parameter for radionuclide i, (other than noble gases)for the inhalation pathway. (mRem/yr per uCi/cm 3)Qaux the limiting release rate contribution from the Auxiliary Building Vent during WGDT releases. (uCi/sec)Qcont the limiting release rate contribution from a containment release.(uCi/sec)Qi total release rate of radionuclide i from all release sources. (uCi/sec)Qiv Total release rate of radionuclide i from release source v. (uCi/sec)Q'i Cumulative release of radionuclide i during the period of interest from all release sources. (uCi)QNG Actual release rate of noble gases from all release sources as calculated from the radionuclide concentrations determined from analyses of samples taken in accordance with Control 3/4.11.2.1, Table 4.11-2.QSITE Total site noble gas release rate limit corresponding to a dose rate at or beyond the SITE BOUNDARY of 500 mRem/yr to the total body or 3000 mRem/yr to the skin. (uCi/sec)RPi~a,o Dose factor for radionuclide i, pathway p, and age group a, and organ o (mRem/yr per uCi/m 3) or(m 2-mRem/yr per uCi/sec).r Distance from the point of release to the location of interest for dispersion calculations. (meters)SF Safety Factor of 0.5 applied to compensate for statistical fluctuations, errors of measurement, and non-uniform distribution of release activity between the stacks.YXj(r) Vertical plume spread with a volumetric correction for a release within the building wake cavity, at a distance, r, for stability class, j, expressed in meters.aj Vertical standard deviation of the plume concentration (in meters), at distance, r, for stability category j.Ujk Wind speed (midpoint of windspeed class k) at ground level (m/sec)during atmosphere stability class j.W' Dispersion parameter for estimating the dose to an individual at the location where the combination of existing pathways and receptor age groups indicates the maximum exposures.
X/Q Annual average relative concentration at the location of interest. (sec/m 3)CPSES -UNITS 1 AND 2- ODCM PART II12-16 Rev. 32 TERM DEFINITION X/0 Highest annual average relative concentration at the SITE BOUNDARY.(sec/m 3) (3.3 x 10-6 sec/m 3 in the NNW sector)Xiv Measured concentration of radionuclide i present in each release source v. (uCi/cm 3).z Fraction of time the wind blows to the sector of interest.1.1 Conversion factor of mRem skin dose per mRad air dose.500 Dose rate limit to the total body of an individual at or beyond the SITE BOUNDARY due to noble gases from all release sources. (mRem/yr)3000 Dose rate limit to the skin of the body of the individual at or beyond the SITE BOUNDARY due to noble gases from all release sources.(mRem/yr)CPSES -UNITS 1 AND 2- ODCM PART II12-17 Rev. 32 TABLE 2.3PATHWAY DOSE RATE PARAMETER (Pi)*BASED ON THE INHALATION PATHWAY FOR THE CHILD AGE GROUP NUCLIDE ORGAN DOSE FACTORS H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI1-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-110M TE-125M TE-1 27M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE O.00E+00 3.59E+04 2.60E+06 0.00E+00 0.OOE+00 4.74E+04 2.07E+04 0.00E+00 0.OOE+00 8.21 E+05 4.26E+04 0.OOE+00 5.99E+05 1.01 E+08 9.14E+05 1.90E+05 2.35E+04 2.79E+03 1.36E+05 1.69E+04 6.73E+03 2.49E+04 1.92E+04 4.81 E+04 1.66E+04 6.51 E+05 6.51 E+04 9.07E+05 7.40E+04 3.92E+04 6.77E+06 1.85E+04 1.08E+04 LIVER 1.12E+03 6.73E+03 1.14E+05 0.OOE+00 4.29E+04 2.52E+04 3.34E+04 1.77E+03 1.31 E+04 4.63E+04 1.13E+05 1.98E+05 0.00E+00 0.OOE+00 O.OOE+00 4.18E+04 9.18E+03 0.OOE+00 0.OOE+00 1.14E+04 2.33E+03 8.55E+03 6.85E+03 4.81 E+04 2.03E+04 1.01 E+06 1.71 E+05 8.25E+05 6.48E+01 1.95E+04 2.12E+06 5.55E+03 8.73E+03 T. BODY 1.12E+03 6.73E+03 9.88E+04 1.54E+02 9.51 E+03 7.77E+03 1.67E+04 3.16E+03 2.26E+04 2.80E+04 7.03E+04 1.14E+05 1.72E+04 6.44E+06 2.44E+04 3.70E+04 6.55E+03 1.07E+03 1.69E+04 9.14E+03 9.14E+02 3.02E+03 3.04E+03 2.73E+04 7.70E+03 2.25E+05 1.16E+05 1.28E+05 4.33E+03 2.90E+03 3.61 E+05 9.14E+02 6.81 E+02 THYROID 1.12E+03.6.73E+03 0.00E+00 8.55E+01 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 1.92E+03 6.07E+03 6.33E+03 1.62E+07 3.85E+06 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 1.12E+03 6.73E+03 0.OOE+00 2.43E+01 1.00E+04 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 7.14E+04 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 5.96E+04 8.62E+03 7.03E+03 1.84E+05 2.12E+04 0.OOE+00 6.36E+04 5.03E+04 7.88E+04 3.38E+04 3.30E+05 9.55E+04 2.82E+05 2.11E+01 8.55E+03 1.17E+06 3.OOE+03 4.81 E+03 LUNG 1.12E+03 6.73E+03 0.OOE+00 1.70E+04 1.58E+06 1.11E+05 1.27E+06 1.11E+06 7.07E+06 2.75E+05 9.95E+05 0.OOE+00 2.16E+06 1.48E+07 2.63E+06 2.23E+06 6.14E+05 6.62E+05 1.43E+07 5.48E+06 4.77E+05 1.48E+06 1.76E+06 0.00E+00 0.00E+00 1.21 E+05 1.45E+04 1.04E+05 1.74E+06 5.44E+05 1.20E+07 4.33E+05 3.28E+05 GI-LLI 1.12E+03 6.73E+03 4.22E+04 1.08E+03 2.29E+04 2.87E+03 7.07E+04 3.44E+04 9.62E+04 6.33E+03 1.63E+04 7.99E+03 1.67E+05 3.43E+05 1.84E+05 6.11E+04 3.70E+04 4.48E+04 4.29E+05 1.00E+05 3.38E+04 7.14E+04 1.82E+05 2.84E+03 5.48E+03 3.85E+03 4.18E+03 3.62E+03 1.02E+05 5.66E+04 3.89E+05 9.73E+04 8.21 E+04 CPSES -UNITS 1 AND 2- ODCM PART II12-20 Rev. 32 TABLE 2.4PATHWAY DOSE FACTORS AGE GROUP: ALL NUCLIDE F H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11OM TE-125M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 PATHWAY: GROUND PLANE ORGAN DOSE FACTORS T. BODY 0.00E+00 0.0 0.OOE+00 0.0Q 0.00E+00 0.0 4.65E+06 5.5 1.39E+09 1.6 0.00E+00 0.0 2.73E+08 3.2 3.79E+08 4.4, 2.15E+10 2.5 0.00E+00 0.0 7.47E+08 8.5 8.97E+06 1.0 2.16E+04 2.5 0.OOE+00 0.0 1.07E+06 1.2 2.45E+08 2.8 1.37E+08 1.6 1.08E+08 1.2 4.22E+08 5.0 3.44E+09 4.0 1.55E+06 2.1 9.17E+04 1.0 1.98E+07 2.3 1.72E+07 2.0 2.45E+06 2.9 6.86E+09 8.0 1.51 E+08 1.7 1.03E+10 1.2 2.06E+07 2.3 1.37E+07 1.5 6.96E+07 8.0 0.OOE+00 0.0 8.39E+06 1.0;KIN OE+00 OE+00 OE+00 OE+06 2E+09 OE+00 1E+08 4E+08 3E+l0 OE+00 9E+08 3E+07 1 E+04 OE+00 1E+06 4E+08 1 E+08 6E+08 6E+08 1 E+09 3E+06 8E+05 1 E+07 9E+07 8E+06 OE+09 1 E+08 OE+10 6E+07 4E+07 5E+07 OE+00 1 E+07 CPSES -UNITS 1 AND 2- ODCM PART II12-21 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: ADULT PATHWAY: GRASS -COW -MILK ORGAN DOSE FACTORS NCIE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H-3 0.OOE+00 7.62E+02 7.62E+02 7.62E+02 7.62E+02 7.62E+02 7.62E+02 C-14 2.25E+04 4.50E+03 4.50E+03 4.50E+03 4.50E+03 4.50E+03 4.50E+03 P-32 1.70E+10 1.06E+09 6.58E+08 0.OOE+00 0.OOE+00 O.00E+00 1.91E+09 CR-51 0.OOE+00 0.OOE+00 2.85E+04 1.70E+04 6.28E+03 3.78E+04 7.17E+06 MN-54 0.OOE+00 8.40E+06 1.60E+06 0.OOE+00 2.50E+06 0.OOE+00 2.57E+07 FE-55 2.51 E+07 1.73E+07 4.04E+06 0.OOE+00 0.OOE+00 9.66E+06 9.93E+06 FE-59 2.97E+07 6.97E+07 2.67E+07 0.OOE+00 0.OOE+00 1.95E+07 2.32E+08 CO-58 0.OOE+00 4.71E+06 1.05E+07 0.OOE+00 0.OOE+00 O.OOE+00 9.54E+07 CO-60 0.OOE+00 1.64E+07 3.61E+07 O.OOE+00 0.OOE+00 0.OOE+00 3.08E+08 I NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11OM TE-1 25M TE-127M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 6.72E+09 1.37E+09 0.OOE+00 1.45E+09 4.67E+10 8.57E+03 9.41 E+02 8.24E+04 1 .102E+03 2.04E+04 5.81 E+07 1.63E+07 4.57E+07 6.01 E+07 2.96E+08 3.87E+06 5.64E+09 2.63E+08 7.37E+09 2.69E+07 4.84E+03 3.57E+05 1.57E+02 9.40E+01 4.65E+08 4.36E+09 2.59E+09 O.OOE+00 0.OOE+00 0.00E+00 3.02E+02 4.58E+04 O.OOE+00 O.OOE+00 5.38E+07 5.89E+06 1.63E+07 2.24E+07 4.23E+08 6.73E+06 1.34E+10 1.04E+09 1.01E+10 3.38E+04 3.27E+03 1.49E+05 6.32E+01 1.09E+02 2.25E+08 1.97E+09 1.21 E+09 4.16E+07 1.15E+10 2.29E+02 2.04E+02 2.46E+04 4.38E+02 2.58E+03 3.19E+07 2.18E+06 5.57E+06 9.51 E+06 2.42E+08 2.05E+06 1.10E+10 7.48E+08 6.60E+09 1.76E+06 3.71 E+02 1.92E+04 7.81 E+00 6.50E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.00E4-00 0.00E+00 O.OOE+00 0.OOE+00 4.89E+06 1.17E+07 2.06E+07 I.39E+II1 9.88E+08 0.00E'-00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 2.91 E+09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 4.74E+02 4.53E+04 3.88E+03 3.93E+04 1.06E+08 6.61 E+07 1.86E+08 2.51E+08 7.25E+08 1.17E+07 4.34E+09 5.78E+08 3.42E+09 1.15E+04 1.52E+03 8.85E+04 3.65E+01 6.35E+01 0.OOE+00 0.OOE+O0 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+OO 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.44E+09 7.92E+07 I1.14E+09 1.94E+04 0.OOE+00 0.OOE+O0 0.OOE+00 O.OOE+00 9.71 E+07 2.74E+09 5.1OE+08 2.32E+08 1.35E+09 4.72E+06 9.57E+05 2.78E+08 1.19E+05 1.32E+06 2.19E+10 6.49E+07 1.53E+08 3.02E+08 1.12E+08 6.04E+06 2.35E+08 1.18E+08 1.95E+08 5.54E+07 1.25E+07 1.21 E+08 6.90E+05 5.22E+05 CPSES -UNITS 1 AND 2- ODCM PART II12-22 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: TEEN PATHWAY: GRASS -COW -MILK ORGAN DOSE FACTORS NUCLIDE NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-110M TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-137 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 4.15E+04 3.15E+10 0.00E+00 0.00E+00 4.46E+07 5.19E+07 0.OOE+00 0.00E+00 1.18E+10 2.11 E+09 0.OOE+00 2.68E+09 6.62E+10 1.58E+04 1.65E+03 1.41 E+05 1.81 E+03 3.76E+04 9.64E+07 3.01 E+07 8.45E+07 1.10E+08 5.38E+08 7.08E+06 9.83E+09 4.49E+08 1.34E+10 4.87E+07 8.89E+03 6.59E+05 2.90E+02 1.81 E+02 LIVER 9.93E+02 8.31 E+03 1.95E+09 0.OOE+00 1.40E+07 3.16E+07 1.21E+08 7.94E+06 2.78E+07 8.36E+08 7.32E+09 4.73E+09 0.OOE+00 0.OOE+00 0.00E+00 5.21 E+02 7.82E+04 0.OOE+00 0.00E+00 9.12E+07 1.08E+07 3.OOE+07 4.09E+07 7.53E+08 1.20E+07 2.31 E+10 1.77E+09 1.78E+10 5.97E+04 5.94E+03 2.73E+05 1.16E+02 1.97E+02 T. BODY 9.93E+02 8.31 E+03 1.22E+09 4.99E+04 2.78E+06 7.37E+06 4.68E+07 1.83E+07 6.27E+07 4:01 E+08 3.42E+09 2.22E+09 7.67E+07 1.63E+10 4.24E+02 3.58E+02 4.30E+04 7.75E+02 4.73E+03 5.55E+07 4.02E+06 1.OOE+07 1.74E+07 4.05E+08 3.66E+06 1.07E+10 1.19E+09 6.21 E+09 3.14E+06 6.82E+02 3.54E+04 1.44E+01 1.18E+01 THYROID 9.93E+02 8.31 E+03 0.OOE+00 2.77E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 8.40E+06 2.01 E+07 3.56E+07 2.20E+1I 1.68E+09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 9.93E+02 8.31 E+03 0.OOE+00 1.09E+04 4.19E+06 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 4.69E+09 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 7.65E+02 7.58E+04 6.39E+03 7.24E+04 1.74E+08 0.OOE+00 3.42E+08 4.61 E+08 1.30E+09 2.11E+07 7.35E+09 9.63E+08 6.06E+09 2.02E+04 2.80E+03 1.63E+05 6.73E+01 1.16E+02 LUNG 9.93E+02 8.31 E+03 0.OOE+00 7.13E+04 0.OOE+00 2.01 E+07 3.82E+07 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 2.81 E+09 1.52E+08 2.36E+09 4.01 E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 GI-LLI 9.93E+02 8.31 E+03 2.65E+09 8.39E+06 2.88E+07 1.37E+07 2.86E+08 1.10E+08 3.62E+08 1.33E+08 3.1OE+09 7.OOE+08 3.19E+08 1.86E+09 6.48E+06 1.20E+06 3.34E+08 1.51 E+05 1.80E+06 2.56E+10 8.87E+07 2.11 E+08 4.14E+08 1.49E+08 9.09E+06 2.88E+08 1.42E+08 2.54E+08 7.51 E+07 1.70E+07 1.66E+08 9.55E+05 7.12E+05 CPSES -UNITS 1 AND 2- ODCM PART II12-23 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: CHILD PATHWAY: GRASS -COW -MILK ORGAN DOSE FACTORS NI IC.I 11"lF BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H-3 O.OOE+00 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 C-14 1.02E+05 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 P-32 7.77E+10 3.64E+09 3.OOE+09 0.00E+00 O.OOE+00 O.OOE+00 2.15E+09 CR-51 O.OOE+00 O.OOE+00 1.02E+05 5.65E+04 1.54E+04 1.03E+05 5.40E+06 MN-54 O.OOE+00 2.1OE+07 5.59E+06 O.OOE+00 5.89E+06 O.OOE+00 1.76E+07 FE-55 1.12E+08 5.94E+07 1.84E+07 O.OOE+00 O.OOE+00 3.36E+07 1.10E+07 FE-59 1.20E+08 1.95E+08 9.70E+07 O.OOE+00 O.OOE+00 5.65E+07 2.03E+08 CO-58 O.OOE+00 1.21E+07 3.72E+07 O.OOE+00 O.QOE+00 O.OE+00 7.08E+07 CO-60 O.OOE+00 4.32E+07 1.27E+08 O.OOE+00 O.OOE+00 O.OOE+00 2.39E+08 NI-63 2.97E+10 1.59E+09 1.01E+09 O.OOE+00 O.OOE+00 O.OOE+00 1.07E+08 ZN-65 4.14E+09 1.10E+10 6.86E+09 O.QOE+00 6.95E+09 O.OOE+00 1.94E+09 RB-86 O.OOE+00 8.78E+09 5.40E+09 O.OOE+00 O.OOE+00 O.OOE+00 5.65E+08 SR-89 6.63E+09 O.OOE+00 1.89E+08 O.OOE+00 O.OOE+00 O.OOE+00 2.57E+08 SR-90 1.12E+11 O.OOE+00 2.84E+10 O.00E+00 O.OOE+00 O.OOE+00 1.51E+09 Y-91 3.91E+04 O.OOE+00 1.05E+03 O.OOE+00 O.OOE+00 O.OOE+00 5.21E+06 ZR-95 3.84E+03 8.43E+02 7.51E+02 0.00E+00 1.21E+03 O.OOE+00 8.80E+05 NB-95 3.18E+05 1.24E+05 8.86E+04 O.OOE+00 1.16E+05 O.OOE+00 2.29E+08 RU-103 4.29E+03 O.OOE+00 1.65E+03 0.00E+00 1.08E+04 O.OOE+00 1.11E+05 RU-106 9.25E+04 O.OOE+00 1.15E+04 O.OOE+00 1.25E+05 O.OOE+00 1.44E+06 AG-110M 2.09E+08 1.41E+08 1.13E+08 O.OOE+00 2.63E+08 O.OOE+00 1.68E+1o TE-125M 7.39E+07 2.OOE+07 9.85E+06 2.07E+07 O.OOE+00 O.OOE+00 7.13E+07 TE-127M 2.08E+08 5.61E+07 2.47E+07 4.98E+07 5.94E+08 O.OOE+00 1.69E+08 TE-129M 2.72E+08 7.59E+07 4.22E+07 8.76E+07 7.98E+08 O.OOE+00 3.31E+08 1-131 1.31E+09 1.31E+09 7.46E+08 4.34E+11 2.16E+09 O.OOE+00 1.17E+08 1-133 1.72E+07 2.13E+07 8.05E+06 3.95E+09 3.55E+07 O.OOE+00 8.58E+06 CS-134 2.27E+10 3.72E+10 7.85E+09 O.QOE+00 1.15E+10 4.14E+09 2.01E+08 CS-136 1.01E+09 2.79E+09 1.80E+09 O.OOE+00 1.49E+09 2.21E+08 9.80E+07 CS-137 3.23E+10 3.09E+10 4.56E+09 O.OOE+00 1.01E+10 3.62E+09 1.93E+08 BA-140 1.18E+08 1.03E+05 6.86E+06 0.00E+00 3.35E+04 6.14E+04 5.96E+07 CE-141 2.19E+04 1.09E+04 1.62E+03 O.OOE+00 4.79E+03 O.OOE+00 1.36E+07 CE-144 1.63E+06 5.09E+05 8.67E+04 O.OOE+00 2.82E+05 O.OOE+00 1.33E+08 PR-143 7.18E+02 2.16E+02 3.56E+01 O.OOE+00 1.17E+02 O.OOE+00 7.75E+05 ND-147 4.45E+02 3.61E+02 2.79E+01 O.OOE+00 1.98E+02 O.OOE+00 5.71E+05 CPSES -UNITS 1 AND 2- ODCM PART II12-24 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: INFANT PATHWAY: GRASS -COW -MILK ORGAN DOSE FACTORS NUC[LIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 N 1-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11 OM TE-125M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-l 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.00E+00 1.82E+05 1.60E+11 0.OOE+00 0.OOE+00 1.35E+08 2.25E+08 0.OOE+00 0.OOE+00 3.50E+10 5.56E+09 0.00E+00 1.26E+10 1.22E+I1 7.34E+04 6.81 E+03 5.94E+05 8.68E+03 1.91 E+05 3.86E+08 1.51 E+08 4.22E+08 5.58E+08 2.72E+09 3.63E+07 3.65E+10 1.98E+09 5.15E+10 2.42E+08 4.34E+04 2.33E+06 1.49E+03 8.83E+02 LIVER 2.38E+03 3.88E+04 9.42E+09 0.OOE+00 3.91 E+07 8.74E+07 3.93E+08 2.43E+07 8.83E+07 2.16E+09 1.91E+10 2.23E+10 0.OOE+00 0.OOE+00 O.OOE+00 1.66E+03 2.45E+05 0.OOE+00 0.00E+00 2.82E+08 5.05E+07 1.40E+08 1.91 E+08 3.21 E+09 5.29E+07 6.81 E+1 0 5.83E+09 6.03E+10 2.42E+05 2.65E+04 9.53E+05 5.56E+02 9.07E+02 T. BODY 2.38E+03 3.88E+04 6.21 E+09 1.61 E+05 8.85E+06 2.34E+07 1.55E+08 6.06E+07 2.08E+08 1.21 E+09 8.79E+09 1.10E+10 3.62E+08 3.10E+10 ,1.95E+03 1.18E+03 1.41 E+05 2.90E+03 2.38E+04 1.87E+08 2.04E+07 5.10E+07 8.59E+07 1.41 E+09 1.55E+07 6.88E+09 2.18E+09 4.27E+09 1.25E+07 3.12E+03 1.30E+05 7.37E+01 5.55E+01 THYROID 2.38E+03 3.88E+04 0.OOE+00 1.05E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 5.08E+07 1.22E+08 2.14E+08 1.05E+12 9.62E+09 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 KIDNEY 2.38E+03 3.88E+04 0.OOE+00.2.30E+04 8.65E+06 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 9.24E+09 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 1.79E+03 1.75E+05 1.81 E+04 2.25E+05 4.03E+08 0.OOE+00 1.04E+09 1.39E+09 3.75E+09 6.22E+07 1.75E+10 2.32E+09 1.62E+10 5.75E+04 8.17E+03 3.85E+05 2.07E+02 3.50E+02 LUNG 2.38E+03 3.88E+04 0.OOE+00 2.05E+05 0.OOE+00 4.27E+07 1.16E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 7.19E+09 4.75E+08 6.55E+09 1.49E+05 o.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 GI-LLI 2.38E+03 3.88E+04 2.17E+09 4.70E+06 1.43E+07 1.11E+07 1.88E+08 6.05E+07 2.1OE+08 1.08E+08 1.61E+10 5.70E+08 2.59E+08 1.52E+09 5.26E+06 8.27E+05 2.07E+08 1.06E+05 1.45E+06 1.46E+10 7.19E+07 1.70E+08 3.33E+08 i.15E+08 8.96E+06 1.85E+08 8.85E+07 1.89E+08 5.94E+07 1.37E+07 1.34E+08 7.84E+05 5.75E+05 CPSES -UNITS 1 AND 2 -ODCM PART II12-25 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: ADULT PATHWAY: GRASS -COW -MEAT ORGAN DOSE FACTORS Mll IC1 I1l _ __ _ _ __1_ __ _ _ __ _ _ __ _ _H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-103 RU-1 06 AG-110M TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-137 BA-1 40 CE-141 CE-144 PR-143 ND-147 BONE 0.00E+00 2.06E+04 4.63E+09 0.00E+00 0.00E+00 2.93E+08 2.66E+08 0.00E+00 0.00E+00 1.89E+10 3.56E+08 0.OOE+00 3.02E+08 1.24E+10 1.13E+06 1.87E+06 2.30E+06 1.05E+08 2.80E+09 6.68E+06 3.59E+08 1.12E+09 1.13E+09 1.08E+07 3.68E-01 6.58E+08 1.21 E+07 8.72E+08 2.90E+07 1.41 E+04 1.46E+06 2.09E+04 7.08E+03 LIVER 3.24E+02 4.13E+03 2.88E+08 0.00E+00 9.18E+06 2.03E+08 6.25E+08 1.82E+07 7.52E+07 1.31 E+09 1.13E+09 4.87E+08 0.00E+00 0.OOE+00 0.00E+00 6.01 E+05 1.28E+06 0.OOE+00 0.00E+00 6.18E+06 1.30E+08 3.99E+08 4.23E+08 1.54E+07 6.41 E-01 1.57E+09 4.78E+07 1.19E+09 3.64E+04 9.51 E+03 6.10E+05 8.40E+03 8.18E+03 T. BODY 3.24E+02 4.13E+03 1.79E+08 7.04E+03 1.75E+06 4.73E+07 2.39E+08 4.09E+07 1.66E+08 6.33E+08 5.12E+08 2.27E+08 8.66E+06 3.05E+09 3.03E+04 4.07E+05 6.87E+05 4.53E+07 3.54E+08 3.67E+06 4.81 E+07 1.36E+08 1.79E+08 8.82E+06 1.95E-01 1.28E+09 3.44E+07 7.82E+08 1.90E+06 1.08E+03 7.83E+04 1.04E+03 4.90E+02 THYROID 3.24E+02 4.13E+03 0.OOE+00 4.21 E+03 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.08E+08 2.85E+08 3.89E+08 5.04E+09 9.42E+01 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 KIDNEY 3.24E+02 4.13E+03 0.00E+00 1.55E+03 2.73E+06 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 7.57E+08 O.00E+00 0.00E+00 O.00E+00 0.00E+00 9.43E+05 1.26E+06 4.02E+08 5.41 E+09 1.22E+07 1.46E+09 4.53E+09 4.73E+09 2.64E+07 1.12E+00 5.07E+08 2.66E+07 4.05E+08 1.24E+04 4.42E+03 3.62E+05 4.85E+03 4.78E+03 LUNG 3.24E+02 4.13E+03 0.00E+00 9.35E+03 0.00E+00 1.13E+08 1.75E+08 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 1.68E+08 3.65E+06 1.35E+08 2.08E+04 0.00E+00 0.00E+00 0.00E+00 0.00E+00 GI-LLI 3.24E+02 4.13E+03 5.21 E+08 1.77E+06 2.81 E+07 1.16E+08 2.08E+09 3.70E+08 1.41 E+09 2.73E+08 7.13E+08 9.59E+07 4.84E+07 3.60E+08 6.24E+08 1.90E+09 7.76E+09 1.23E+10 1.81E+11 2.52E+09 1.43E+09 3.74E+09 5.71 E+09 4.06E+06 5.76E-01 2.74E+07 5.43E+06 2.31 E+07 5.96E+07 3.64E+07 4.93E+08 9.17E+07 3.93E+07 CPSES -UNITS 1 AND 2- ODCM PART 1[ 2-26 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: TEEN PATHWAY: GRASS ORGAN DOSE FACTORS-COW -MEAT NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-106 AG-11 OM TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-134 CS-1 36 CS-1 37 BA-1 40 CE-141 CE-144 PR-143 ND-147 BONE O.OOE+00 1.74E+04 3.91 E+09 O.OOE+00 0.OOE+00 2.38E+08 2.12E+08 0.OOE+00 O.OOE+00 1.52E+10 2.50E+08 0.OOE+00 2.55E+08 8.04E+09 9.54E+05 1.50E+06 1.79E+06 8.56E+07 2.36E+09 5.06E+06 3.03E+08 9.41 E+08 9.49E+08 8.93E+06 3.08E-01 5.23E+08 9.43E+06 7.24E+08 2.39E+07 1.18E+04 1.23E+06 1.76E+04 6.23E+03 LIVER 1.93E+02 3.49E+03 2.42E+08 O.OOE+00 7.O0E+06 1.69E+08 4.95E+08 1.40E+07 5.83E+07 1.07E+09 8.68E+08 4.06E+08 0.OOE+00 0.OOE+00 0.OOE+00 4.73E+05 9.95E+05 0.00E+00 O.OOE+00 4.78E+06 1.09E+08 3.34E+08 3.52E+08 1.25E+07 5.22E-01 1.23E+09 3.71 E+07 9.63E+08 2.93E+04 7.87E+03 5.08E+05 7.03E+03 6.78E+03 T. BODY 1.93E+02 3.49E+03 I .52E+08 5.63E+03 1.39E+06 3.94E+07 1.91 E+08 3.24E+07 1.31 E+08 5.15E+08 4.05E+08 1.91 E+08 7.29E+06 1.99E+09 2.56E+04 3.25E+05 5.48E+05 3.66E+07 2.97E+08 2.91 E+06 4.05E+07 1'.12E+08 1.50E+08 6.72E+06 1.59E-01 5.71 E+08 2.49E+07 3.35E+08 1.54E+06 9.05E+02 6.60E+04 8.76E+02 4.06E+02 THYROID 1.93E+02 3.49E+03 O.OOE+00 3.13E+03 O.OOE+00 O.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 8.46E+07 2.24E+08 3.06E+08 3.65E+09 7.29E+01 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 KIDNEY 1.93E+02 3.49E+03 0.OOEO00 1.23E+03 2.09E+06 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 5.56E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 6.95E+05 9.64E+05 3.02E+08 4.54E+09 9.13E+06 0.OOE+00 3.81 E+09 3.97E+09 2.15E+07 9.16E-01 3.91 E+08 2.02E+07 3.28E+08 9.94E+03 3.71 E+03 3.03E+05 4.08E+03 3.98E+03 LUNG 1.93E+02 3.49E+03 0.OOE+00 8.03E+03 O.OOE+00 1.07E+08 1.56E+08 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 1.49E+08 3.18E+06 1.27E+08 1.97E+04 0.OOE+00 0.OOE+00 O.OOE+00 O.OE+00 GI-LLI 1.93E+02 3.49E+03 3.29E+08 9.46E+05 1.44E+07 7.31 E+07 1.17E+09 1.94E+08 7.60E+08 1.71 E+08 3.68E+08 6.OOE+07 3.03E+07 2.26E+08 3.91 E+08 1.09E+09 4.25E+09 7.15E+09 1.13E+11 1.34E+09 8.94E+08 2.35E+09 3.56E+09 2.47E+06 3.95E-01 1.53E+07 2.99E+06 1.37E+07 3.69E+07 2.25E+07 3.09E+08 5.79E+07 2.44E+07 I CPSES -UNITS 1 AND 2- ODCM PART II12-27 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: CHILD PATHWAY: GRASS -COW -MEAT ORGAN DOSE FACTORS NUJCIDEfl NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-103 RU-1 06 AG-11OM TE-1 25M TE-127M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE O.OOE+00 3.28E+04 7.38E+09 0.OOE+00 0.OOE+00 4.57E+08 3.77E+08 O.OOE+00 0.OOE+00 2.91E+10 3.76E+08 0.OOE+00 4.82E+08 1.04E+10 1.80E+06 2.66E+06 3.1OE+06 1.55E+08 4.44E+09 8.39E+06 5.69E+08 1.78E+09 1.79E+09 1.66E+07 5.72E-01 9.23E+08 1.63E+07 1.33E+09 4.42E+07 2.22E+04 2.32E+06 3.33E+04 1.17E+04 LIVER 2.34E+02 6.56E+03 3.45E+08 0.OOE+00 8.01 E+06 2.43E+08 6.10E+08 1.64E+07 6.93E+07 1.56E+09 1.OOE+09 5.76E+08 0.OOE+00 0.OOE+00 0.00E+00 5.86E+05 1.12E+06 0.OOE+00 0.OOE+00 5.67E+06 1.54E+08 4.78E+08 5.OOE+08 1.67E+07 7.08E-01 1.51 E+09 4.48E+07 1.28E+09 3.87E+04 1.11E+04 7.26E+05 1.00E+04 9.48E+03 T. BODY 2.34E+02 6.56E+03 2.85E+08 8.78E+03 2.13E+06 7.52E+07 3.04E+08 5.03E+07 2.04E+08 9.91 E+08 6.22E+08 3.54E+08 1.38E+07 2.64E+09 4.82E+04 5.21 E+05 8.63E+05 5.96E+07 5.54E+08 4.53E+06 7.59E+07 2.11 E+08 2.78E+08 9.48E+06 2.68E-01 3.19E+08 2.90E+07 1.89E+08 2.58E+06 1.65E+03 1.24E+05 1.65E+03 7.34E+02 THYROID 2.34E+02 6.56E+03 0.00E+00 4.88E+03 0.OOE+00 0.00E+00 0.00E+00 O.OE+00 0.00E+00 O.OOE+00 O.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 1.60E+08 4.25E+08 5.77E+08 5.52E+09 1.31 E+02 0.00E+00 0.O0E+00 0.00E+00 0.OOE+00 0.OOE+00 O.00E+00 O.00E+00 0.00E+00 KIDNEY 2.34E+02 6.56E+03 0.00E+00 1.33E+03 2.25E+06 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 6.31 E+08 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 8.38E+05 1.13E+06 3.90E+08 6.OOE+09 1.06E+07 0.00E+00 5.06E+09 5.26E+09 2.74E+07 1.18E+00 4.69E+08 2.39E+07 4.16E+08 1.26E+04 4.86E+03 4.02E+05 5.42E+03 5.20E+03 LUNG 2.34E+02 6.56E+03 0.00E+00 8.90E+03 O.OOE+00 1.37E+08 1.77E+08 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 1.68E+08 3.56E+06 1.50E+08 2.31 E+04 0.O0E+00 0.OOE+00 0.00E+00, O.00E+00 GI-LLI 2.34E+02 6.56E+03 2.04E+08 4.66E+05 6.73E+06 4.49E+07 6.35E+08 9.58E+07 3.84E+08 1.05E+08 1.76E+08 3.71 E+07 1.87E+07 1.40E+08 2.40E+08 6.11E+08 2.23E+09 4.01E+09 6.91E+10 6.74E+08 5.49E+08 1.44E+09 2.18E+09 1.48E+06 2.85E-01 8.16E+06 1.57E+06 8.00E+06 2.24E+07 1.38E+07 1.89E+08 3.60E+07 1.50E+07 CPSES -UNITS 1 AND 2- ODCM PART II12-28 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: INFANT PATHWAY: GRASS-COW -MEAT NORGAN DOSE FACTORS NUJCIDEfl H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11 OM TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-134 CS-1 36 CS-137 BA-140 CE-141 CE-144 PR-143 ND-147 BN E 0.OOE+00 0 0.00E+00 0.OOE+00 0.00E+00 0.00E+O0 O.OOE+00 0.00E+00 0.00E+00 O.00E+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+OO 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OQE+00 0.OOE+00 0.OOE+00 0.OOE+O0 O.OOE+0O 0.OOE+0O 0.OOE+00 0.00E+0O O.00E+00 LIVER 0.OOE+00 0 0 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 O.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 O.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.O0E+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 T. BODY THYROID 0.OOE+00 0.OOE+00 0 0 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 O.OOE+00 O.00E+00 0.OOE+00 0.00E+00 O.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 O.OOE+00 0.OOE+00.
0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 O.00E+00 O.OOE+00 0.00E+00 O.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 KIDNEY 0.OOE+00 0 0.00E+O0 0.00E+00 0.00E+00 0.00E+00 O.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE-'00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 LUNG 0.00E+00 0 O.OOE+00-O.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 GI-LLI 0.OOE+00 0 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CPSES -UNITS 1 AND 2- ODCM PART II12-29 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: ADULT PATHWAY: GRASS -GOAT -MILK ORGAN DOSE FACTORS NULiCLI DE NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-106 AG-110M TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 2.25E+04 2.05E+10 0.OOE+00 0.OOE+00 3.27E+05 3.87E+05 0.OOE+00 0.OOE+00 8.08E+08 1.65E+08 0.OOE+00 3.05E+09 9.84E+10 1.03E+03 1.13E+02 9.92E+03 1.22E+02 2.45E+03 6.99E+06 1.96E+06 5.50E+06 7.23E+06 3.56E+08 4.65E+06 1.70E+10 7.92E+08 2.22E+10 3.24E+06 5.82E+02 4.30E+04 1.90E+01 1.13E+01 LIVER 1.56E+03 4.50E+03 1.27E+09 0.00E+00 1.01 E+06 2.26E+05 9.09E+05 5.66E+05 1.97E+06 5.60E+07 5.24E+08 3.12E+08 0.OOE+00 0.OOE+00 0.OOE+00 3.63E+01 5.52E+03 0.OOE+00 0.OOE+00 6.47E+06 7.09E+05 1.97E+06 2.70E+06 5.09E+08 8.16E+06 4.04E+10 3.13E+09 3.03E+10 4.07E+03 3.94E+02 1.80E+04 7.60E+00 1.31E+01 T. BODY 1.56E+03 4.50E+03 7.92E+08 3.43E+03 1.93E+05 5.26E+04 3.48E+05 1.27E+06 4.35E+06 2.71 E+07 2.37E+08 1.45E+08 8.76E+07 2.41E+10 2.76E+01 2.46E+01 2.97E+03 5.27E+01 3.1OE+02 3.84E+06 2.62E+05 6.70E+05 1.14E+06 2.92E+08 2.47E+06 3.30E+10 2.25E+09 1.99E+10 2.12E+05 4.47E+01 2.31 E+03 9.40E-01 7.82E-01 THYROID 1.56E+03 4.50E+03 0.OOE+00 2.05E+03 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 5.89E+05 1.41 E+06 2.48E+06 1.67E+11 1.19E+09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 1.56E+03 4.50E+03 0.OOE+00 7.56E+02 3.01 E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 3.51 E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 5.70E+01 5.45E+03 4.67E+02 4.73E+03 1.27E+07 7.96E+06 2.23E+07 3.02E+07 8.73E+08 1.41 E+07 1.31E+10 1.74E+09 1.03E+10 1.38E+03 1.83E+02 1.07E+04 4.39E+00 7.65E+00 LUNG 1.56E+03 4.50E+03 0.OOE+00 4.55E+03 0.OOE+00 1.26E+05 2.54E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 4.34E+09 2.38E+08 3.42E+09 2.33E+03 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 GI-LLI 1.56E+03 4.50E+03 2.30E+09 8.63E+05 3.1OE+06 1.30E+05 3.03E+06 1.15E+07 3.70E+07 1.17E+07 3.30E+08 6.14E+07 4.89E+08 2.84E+09 5.68E+05 1.15E+05 3.35E+07 1.43E+04 1.59E+05 2.64E+09 7.81 E+06 1.84E+07 3.64E+07 1.34E+08 7.28E+06 7.07E+08 3.55E+08 5.87E+08 6.67E+06 1.51 E+06 1.45E+07 8.30E+04 6.28E+04 CPSES -UNITS 1 AND 2- ODCM PART II 2-30 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: TEEN PATHWAY: GRASS -GOAT -MILK ORGAN DOSE FACTORS NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11 OM TE-1 25M TE-127M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.00E+00 4.15E+04 3.78E+10 0.OOE+00 0.00E+00 5.79E+05 6.74E+05 0.00E+00 0.00E+00 1.42E+09 2.53E+08 0.00E+00 5.62E+09 1.39E+I 1 1.90E+03 1.98E+02 1.69E+04 2.17E+02 4.50E+03 1.16E+07 3.61 E+06 1.01 E+07 1.32E+07 6.45E+08 8.49E+06 2.95E+10 I .35E+09 4.02E+10 5.84E+06 1.07E+03 7.90E+04 3.48E+01 2.18E+01 LIVER 2.04E+03 8.31 E+03 2.34E+09 O.OOE+00 1.68E+06 4.11E+05 1.57E+06 9.53E+05 3.34E+06 1.OOE+08 8.78E+08 5.67E+08 0.00E+00 0.00E+00 O.00E+00 6.25E+01 9.38E+03 0.00E+00 0.00E+00 1.09E+07 1.30E+06 3459E+06 4.90E+06 9.03E+08 1.44E+07 6.93E+10 5.30E+09 5.34E+10 7.16E+03 7.12E+02 3.27E+04 1.39E+01 2.37E+01 T. BODY 2.04E+03 8.31 E+03 1.46E+09 5.99E+03 3.34E+05 9.58E+04 6.08E+05 2.20E+06 7.52E+06 4.81 E+07 4.10E+08 2.67E+08 1.61 E+08 3.43E+10 5.09E+01 4.30E+01 5.16E+03 9.29E+01 5.68E+02 6.65E+06 4.82E+05 1.20E+06 2.09E+06 4.85E+08 4.40E+06 3.22E+10 3.56E+09 1.86E+10 3.76E+05 8.18E+01 4.25E+03 1.73E+00 1.42E+00 THYROID 2.04E+03 8.31 E+03 0.00E+00 3.33E+03 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 O.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.01 E+06 2.41E+06 4.26E+06 2.64E+1 1 2.01 E+09 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 KIDNEY 2.04E+03 8.31 E+03 0.00E+00 1.31 E+03 5.02E+05 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 5.62E+08 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 9.18E+01 9.09E+03 7.66E+02 8.69E+03 2.09E+07 0.00E+00 4.11E+07 5.53E+07 1.56E+09 2.53E+07 2.20E+10 2.89E+09 1.82E+10 2.43E+03 3.35E+02 1.95E+04 8.08E+00 1.39E+01 LUNG 2.04E+03 8.31 E+03 0.00E+00 8.55E+03 0.00E+00 2.61 E+05 4.96E+05 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 8.41 E+09 4.55E+08 7.07E+09 4.81 E+03 0.OOE+00 0.0OE+00 0.00E+00 0.00E+00 GI-LLI 2.04E+03 8.31E+03 3.18E+09 1.01E+06 3.45E+06 1.78E+05 3.72E+06 1.31 E+07 4.35E+07 1.60E+07 3.72E+08 8.40E+07 6.69E+08 3.90E+09 7.78E+05 1.44E+05 4.01 E+07 1.82E+04 2.16E+05 3.07E+09'I.06E+07 2.52E+07 4.96E+07 1.79E+08 1.09E+07 8.62E+08 4.27E+08, 7.60E+08 9.01 E+06 2.04E+06 1.99E+07 1.15E+05 8.54E+04 CPSES -UNITS 1 AND 2- ODCM PART II12-31 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: CHILD PATHWAY: GRASS -GOAT -MILK ORGAN DOSE FACTORS NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 N 1-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-103 RU-1 06 AG-11 OM TE-125M TE-127M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37.BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 1.02E+05.9.32E+10 0.OOE+00 0.OOE+00 1.45E+06 1.56E+06 0.OOE+00 0.00E+00 3.56E+09 4.96E+08 0.00E+00 1.39E+10 2.35E+1 1 4.69E+03 4.60E+02 3.82E+04 5.14E+02 1.11E+04 2.51 E+07 8.86E+06 2.50E+07 3.26E+07 1.57E+09 2.06E+07 6.80E+10 3.04E+09 9.68E+10 1.41 E+07 2.63E+03 1.95E+05 8.61 E+01 5.34E+01 LIVER 3.20E+03 2.04E+04 4.36E+09 0.OOE+00 2.52E+00 7.71 E+00 2.53E+06 1.46E+06 5.18E+06 1.91 E+08 1.32E+09 1.05E+09 0.OOE+00 0.OOE+00 0.OOE+00 1.01E+02 1.49E+04 0.OOE+00 0.OOE+00 1.69E+07 2.40E+06 6.72E+06 9.1OE+06 1.57E+09 2.55E+07 1.12E+11 8.36E+09 9.26E+ 10 1.24E+04 1.31 E+03 6.11E+04 2.59E+01 4.33E+01 T. BODY 3.20E+03 2.04E+04 3.59E+09 1.22E+04 6.71 E+05 2.39E+05 1.26E+06 4.46E+06 1.53E+07 1.21 E+08 8.22E+08 6.47E+08 3.97E+08 5.95E+10 1.25E+02 9.OOE+01 1.06E+04 1.98E+02 1.38E+03 1/35E+07 1.18E+06 2.96E+06 5.06E+06 8.95E+08 9.66E+06 2.35E+10 5.41 E+09 1.37E+10 8.23E+05 1.95E+02 1.04E+04 4.27E+00 3.35E+00 THYROID 3.20E+03 2.04E+04 0.OOE+00 6.78E+03 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 2.49E+06 5.97E+06 1.05E+07 5.21 E+11 4.74E+09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 3.20E+03 2.04E+04 0.OOE+00 1.85E+03 7.06E+05 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 8.33E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.45E+02 1.40E+04 1.29E+03 1.50E+04 3.15E+07 0.OOE+00 7.12E+07 9.56E+07 2.58E+09 4.25E+07 3.46E+ 10 4.45E+09 3.02E+10 4.02E+03 5.74E+02 3.38E+04 1.40E+01 2.37E+01 LUNG 3.20E+03 2.04E+04 0.OOE+00 1.24E+04 0.OOE+00 4.36E+05 7.34E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.24E+10 6.64E+08 1.09E+10 7.37E+03 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 GI-LLI 3.20E+03 2.04E+04 2.58E+09 6.48E+05 2.11E+06 1.43E+05 2.64E+06 8.49E+06 2.87E+07 1.28E+07 2.32E+08 6.77E+07 5.39E+08 3.16E+09 6.24E+05 1.05E+05 2.75E+07 1.33E+04 1.73E+05 2.01 E+09 8.55E+06 2.02E+07 3.97E+07 1.40E+08 1.03E+07 6.01 E+08 2.94E+08 5.80E+08 7.15E+06 1.63E+06 1.59E+07 9.29E+04 6.85E+04 CPSES -UNITS 1 AND 2- ODCM PART II12-32 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: INFANT PATHWAY: GRASS -GOAT -MILK NUCLIDE BONE H-3 0.00E+00 C-14 1.82E+05 P-32 1.92E+11 CR-51 0.00E+00 MN-54 0.00E+00 FE-55 1.76E+06 FE-59 2.92E+06 CO-58 0.00E+00 CO-60 O.00E+00 NI-63 4.19E+09 ZN-65 6.67E+08 RB-86 O.OOE+00 SR-89' 2.65E+10 SR-90 2.55E+1 1 Y-91 8.80E+03 ZR-95 8.17E+02 NB-95 7.13E+04 RU-103 1.04E+03 RU-1 06 2.28E+04 AG-110M 4.63E+07 TE-125M 1.81 E+07 TE-127M 5.06E+07 TE-129M 6.69E+07 1-131 3.27E+09 1-133 4.36E+07 CS-134 1.09E+11 CS-1 36 5.94E+09 CS-137 1.54E+11 BA-140 2.90E+07 CE-141 5.21 E+03 CE-144 2.79E+05 PR-143 1.78E+02 ND-147 1.06E+02 ORGAN DOSE. FACTORS LIVER 4.86E+03 3.88E+04 1.13E+10 0.OOE+00 4.68E+06 1.14E+06 5.1OE+06 2.91 E+06 1.06E+07 2.59E+08 2.29E+09 2.67E+09 0.OOE+00 0.00E+00 0.00E+00 1.99E+02 2.93E+04 0.00E+00 0.00E+00 3.38E+07 6.05E+06 1.68E+07 2.29E+07 3.85E+09 6.35E+07 2.04E+11 1.75E+10 1.81 E+I 1 2.90E+04 3.18E+03 1.14E+05 6.66E+01 1.09E+02 T. BODY 4.86E+03 3.88E+04 7.44E+09 1.94E+04 1.06E+06 3.03E+05 2.01E+06 7.26E+06 2.50E+07 1.46E+08 1.05E+09 1.32E+09 7.59E+08 6.50E+10 2.34E+02 1.41E+02 1.70E+04 3.48E+02 2.85E+03 2.24E+07 2.45E+06 6.12E+06 1.03E+07 1.69E+09 1.86E+07 2.06E+10 6.52E+09 1.28E+10 1.50E+06 3.74E+02 1.56E+04 8.83E+00 6.66E+00 THYROID 4.86E+03 3.88E+04 0.00E+00 1.26E+04 0.00E+00 0.00E+00 0.OOE+00, 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 6.09E+06 1.46E+07 2.57E+07 1.27E+12 1.15E+10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 KIDNEY 4.86E+03 3.88E+04 0.OOE+00 2.76E+03 1.04E+06 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 1.11E+09 0.00E+00 0.00E+00 0.00E+00 0.00E+00 2.15E+02 2.1OE+04 2.17E+03 2.70E+04 4.84E+07 0.00E+00 1.24E+08 1.67E+08 4.50E+09 7.46E+07 5.26E+10 6.96E+09 4.85E+1 0 6.89E+03 9.79E+02 4.62E+04 2.48E+01 4.19E+01 LUNG 4.86E+03 3.88E+04 0.OOE+00 2.46E+04 0.00E+00 5.55E+05 1.51 E+06 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 2.15E+10 1.42E+09 1.96E+10 1.78E+04 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 GI-LLI 4.86E+03 3.88E+04 2.60E+09 5.64E+05 1.72E+06 1.44E+05 2.44E+06 7.25E+06 2.52E+07 1.29E+07 1.93E+09 6.83E+07 5.44E+08 3.19E+09 6.31 E+05 9.91 E+04 2.48E+07 1.27E+04 1.73E+05 1.75E+09 8.62E+06 2.04E+07 3.99E+07 1.37E+08 1.07E+07 5.55E+08 2.65E+08 5.65E+08 7.13E+06 1.64E+06 1.60E+07 9.40E+04 6.89E+04 CPSES -UNITS 1 AND 2- ODCM PART II12-33 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: ADULT PATHWAY: VEGETATION ORGAN DOSE FACTORS NULJI IEl NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 N 1-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-106 AG-11OM TE-1 25M TE-127M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 5.56E+04 1.40E+09 0.OOE+00 0.OOE+00 2.1OE+08 1.26E+08 0.OOE+00 0.OOE+00 1.04E+10 3.17E+08 0.OOE+00 9.98E+09 6.05E+1I 5.12E+06 1.17E+06 1.42E+05 4.77E+06 1.93E+08 1.05E+07 9.66E+07 3.49E+08 2.51E+08 8.08E+07 2.09E+06 4.67E+09 4.28E+07 6.36E+09 1.29E+08 1.97E+05 3.29E+07 6.25E+04 3.34E+04 LIVER 2.26E+03 1.11 E+04 8.69E+07 0.OOE+00 3.13E+08 1.45E+08 2.97E+08 3.07E+07 1.67E+08 7.21 E+08 1.01 E+09 2.19E+08 O.OE+00 0.OOE+00 0.OOE+00 3.77E+05 7.92E+04 0.OOE+00 0.OOE+00 9.75E+06 3.50E+07 1.25E+08 9.37E+07 1.16E+08 3.63E+06 1.11E+10 1.69E+08 8.70E+09 1.62E+05 1.33E+05 1.38E+07 2.51E+04 3.85E+04 T. BODY 2.26E+03 1.11E+04 5.40E+07 4.64E+04 5.97E+07 3.38E+07 1.14E+08 6.89E+07 3.69E+08 3.49E+08 4.56E+08 1.02E+08 2.86E+08 1.48E+11 1.37E+05 2.55E+05 4.26E+04 2.06E+06 2.44E+07 5.79E+06 1.29E+07 4.26E+07 3.97E+07 6.62E+07 1.11E+06 9.08E+09 1.22E+08 5.70E+09 8.47E+06 1.51E+04 1.77E+06 3.1OE+03 2.31 E+03 THYROID 2.26E+03 1.11E+04 0.OOE+00 2.77E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 2.90E+07 8.93E+07 8.63E+07 3.79E+10 5.34E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 KIDNEY 2.26E+03 1.11E+04 0.OOE+00 1.02E+04 9.31 E+07 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 6.75E+08 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 5.91 E+05 7.83E+04 1.82E+07 3.72E+08 1.92E+07 3.93E+08 1.42E+09 1.05E+09 1.98E+08 6.33E+06 3.59E+09 9.41 E+07 2.95E+09 5.52E+04.6.20E+04 8.16E+06 1.45E+04 2.25E+04 LUNG 2.26E+03 1.11E+04 0.OOE+00 6.15E+04 0.OOE+00 8.08E+07 8.29E+07 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.19E+09 1.29E+07 9.81 E+08 9.29E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 GI-LLI 2.26E+03 1.11E+04 1.57E+08 1.17E+07 9.58E+08 8.31 E+07 9.89E+08 6.23E+08 3.14E+09 1.50E+08 6.36E+08 4.32E+07 1.60E+09 1.75E+10 2.82E+09 1.19E+09 4.81 E+08 5.57E+08 1.25E+10 3.98E+09 3.86E+08 1.17E+09 1.26E+09 3.05E+07 3.26E+06 1.94E+08 1.92E+07 1.68E+08 2.66E+08 5.1OE+08 1.11E+10 2.74E+08 1.85E+08 CPSES -UNITS 1 AND 2- ODCM PART II12-34 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: TEEN PATHWAY: VEGETATION ORGAN DOSE FACTORS NIJCIIflF:
H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-106 AG-11OM TE-1 25M TE-127M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1i37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 9.01 E+04 1.60E+09 0.OOE+00 0.OOE+00 3.26E+08 1.80E+08 0.OOE+00 0.OOE+00 1.61E+10 4.24E+08 0.OOE+00 1.52E+10 7.51E+l1 7.84E+06 1.72E+06 1.92E+05 6.82E+06 3.09E+08 1.52E+07 1.48E+08 5.52E+08 3.61 E+08 7.69E+07 1.94E+06 7.1OE+09 4.39E+07 1.01E+10 1.39E+08 2.83E+05 5.28E+07 6.99E+04 3.62E+04 LIVER 2.59E+03 1.80E+04 9.91 E+07 0.OOE+00 4.54E+08 2.31 E+08 4.19E+08 4.36E+07 2.49E+08 1.13E+09 1.47E+09 2.73E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.43E+05 1.07E+05 0.OOE+00 O.00E+00 1.43E+07 5.34E+07 1.96E+08 1.34E+08 1.08E+08 3.29E+06 1.67E+10, 1.73E+08 1.35E+10 1.71 E+05 1.89E+05 2.18E+07 2.79E+04 3.94E+04 T. BODY 2.59E+03 1.80E+04 6.20E+07 6.16E+04 9.01 E+07 5.39E+07 1.62E+08 1.01 E+08 5.60E+08 5.45E+08 6.86E+08 1.28E+08 4.34E+08 1.85E+ 11 2.10E+05 3.73E+05 5.87E+04 2.92E+06 3.90E+07 8.72E+06 1.98E+07 6.56E+07 5.72E+07 5.78E+07 1.OOE+06 7.75E+09 1.16E+08 4.69E+09 8.97E+06 2.17E+04 2.83E+06 3.48E+03 2.36E+03 THYROID 2.59E+03 1.80E+04 0.OOE+00 3.42E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00-0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.001E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 4.14E+07 1.31 E+08 1.17E+08 3.14E+10 4.59E+08 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 KIDNEY 2.59E+03 1.80E+04 0.OOE+00 1.35E+04 1.36E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 9.42E+08 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 7.98E+05 1.03E+05 2.41 E+07 5.97E+08 2.74E+07 0.OOE+00 2.24E+09 1.51 E+09 1.85E+08 5.77E+06 5.31 E+09 9.41 E+07 4.59E+09 5.78E+04 8.90E+04 1.30E+07 1.62E+04 2.31 E+04 LUNG 2.59E+03 1.80E+04 0.OOE+00 8.79E+04 0.OOE+00 1.47E+08 1.32E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00k+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 2.03E+09 1.48E+07 1.78E+09 1.15E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 GI-LLI 2.59E+03 1.80E+04 1.34E+08 I .03E+07 9.32E+08 1.OOE+08 9.91 E+08 6.01 E+08 3.24E+09 1.81 E+08 6.23E+08 4.04E+07 1.80E+09 2.11E+10 3.22E+09 1.25E+09 4.56E+08 5.70E+08 1.48E+10 4.03E+09 4.37E+08 1.37E+09 1.36E+09 2.13E+07 2.49E+06 2.08E+08 1.39E+07 1.92E+08 2.15E+08 5.41 E+08 1.33E+10 2.30E+08 1.42E+08 I CPSES -UNITS 1 AND 2- ODCM PART II12-35 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: CHILD PATHWAY: VEGETATION NUCLIDE BONE H-3 0.OOE+00 C-14 2.17E+05 P-32 3.35E+09 CR-51 0.00E+00 MN-54 0.OOE+00 FE-55 8.01 E+08 FE-59 3.98E+08 CO-58 O.OOE+00 CO-60 O.OOE+00 NI-63 3.95E+10 ZN-65 8.12E+08 RB-86 O.OOE+00 SR-89 3.60E+10 SR-90 1.24E+12 Y-91 1.87E+07 ZR-95 3.86E+06 NB-95 4.11E+05 RU-103 1.53E+07 RU-1 06 7.45E+08 AG-110M 3.21E+07 TE-125M 3.51E+08 TE-127M 1.32E+09 TE-129M 8.40E+08 1-131 1.43E+08 1-133 3.53E+06 CS-134 1.60E+10 CS-1 36 8.28E+07 CS-137 2.39E+10 BA-140 2.79E+08 CE-141 6.57E+05 CE-144 1.27E+08 PR-143 1.45E+05 ND-147 7.15E+04 ORGAN DOSE FACTORS ORGAN DOSE FACTORS LIVER 4.02E+03 4.34E+04 1.57E+08 0.OOE+00 6.65E+08 4.25E+08 6.44E+08 6.44E+07 3.78E+08 2.11E+09 2.16E+09 4.51 E+08 0.00E+00 0.OOE+00 0.OOE+00 8.48E+05 1.60E+05 0.OOE+00 0.OOE+00 2.17E+07 9.50E+07 3.56E+08 2.35E+08 1.44E+08 4.37E+06 2.63E+10 2.28E+08 2.29E+10 2.44E+05 3.28E+05 3.99E+07 4.36E+04 5.79E+04 T. BODY 4.02E+03 4.34E+04 1.29E+08 1.17E+05 1.77E+08 1.32E+08 3.21 E+08 1.97E+08 1.12E+09 1.34E+09 1.35E+09 2.77E+08 1.03E+09 3.15E+l1 4.99E+05 7.55E+05 1.14E+05 5.90E+06 9.30E+07 1.73E+07 4.67E+07 1.57E+08 1.30E+08 8.18E+07 1.65E+06 5.55E+09 1.47E+08 3.38E+09 1.63E+07 4.86E+04 6.79E+06 7.21 E+03 4.49E+03 THYROID 4.02E+03 4.34E+04 0.OOE+00 6.49E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 9.84E+07 3.16E+08 2.71 E+08 4.76E+10 8.12E+08 0.OOE+00 0.OOE+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 4.02E+03 4.34E+04 0.OOE+00 1.77E+04 1.86E+08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.36E+09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.21 E+06 1.50E+05 3.86E+07 1.01 E+09 4.04E+07 0.OOE+00 3.77E+09 2.47E+09 2.36E+08 7.28E+06 8.15E+09 1.21 E+08 7.46E+09 7.96E+04 1.44E+05 2.21 E+07 2.36E+04 3.18E+04 LUNG 4.02E+03 4.34E+04 O.00E+00 1.18E+05 0.OOE+00 2.40E+08 1.87E+08 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 2.93E+09 1.81 E+07 2.68E+09 1.46E+05 0.OOE+00 0.OOE+00 0.00E+00 O.OOE+00 GI-LLI 4.02E+03 4.34E+04 9.25E+07 6.20E+06 5.58E+08 7.87E+07 6.71 E+08 3.76E+08 2.1OE+09 1.42E+08 3.80E+08 2.90E+07 1.39E+09 1.67E+l0 2.49E+09 8.85E+08 2.96E+08 3.97E+08 1.16E+10 2.58E+09 3.38E+08 1.07E+09 1.02E+09 1.28E+07 1.76E+06 1.42E+08 8.OOE+06 1.43E+08 1.41 E+08 4.09E+08 1.04E+10 1.57E+08 9.18E+07 CPSES -UNITS 1 AND 2- ODCM PART II12-36 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: INFANT PATHWAY: VEGETATION ORGAN DOSE FACTORS NUCLIDE NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11 OM TE-1 25M TE-127M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 0.OOE+0O 0.OOE-i00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+0O O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OQE+0O 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+0O O.OOE+O0 0.OOE+00 O.OQE+00 O.OOE+0O O.OOE--00 0.OOE+00 O.OOE+00 0.OOE+0O O.OOE+0O 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+O0 O.OOE+00 O.OOE+00 LIVER 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.0OE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.00E+00 T. BODY 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+0O O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+0O 0.OOE+0O 0.OOE+O0 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+0Q 0.OOE+0O 0.OOE+Q0 0.OOE+00 0.OOE+0O 0.OOE+00 0.OOE+O0 THYROID O.OOE--00 0.OOE+00 0.OOE+0O O.OOE+00 0.OOE+00 O.OOE+O0 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+OO 0.OOE+0O 0.OOE+00 0.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+O0 0.OOE+00 O.00E4-00 0.OOE+00 O.OOE+00 0.OOE+0O 0.OOE+00 0.OOE+00 0.OOE+O0 O.OOE+00 O.OOE+00 0.OOE+0O 0.OOE+0O O.OOE+00 O.OOE+0O 0.OOE+00 KIDNEY 0.OOE+00 O.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+0O O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+OO 0.OOE+O0 0.OOE+O0 0.00E4-00 O.OOE+0Q 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+0O 0.OOE+00 0.OOE+O0 0.OOE+00 O.OOE+0O O.OOE+00 0.OOE+0O 0.OOE+00 O.OOE+00 O.OOE+O0 O.OOE+00 O.OOE+00 0.OOE+00 LUNG O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+OO O.OOE+00 0.OOE+00 0.OOE+O0 0.OOE+0O 0.OOE+0O O.OOE+00 0.OOE+00 0.OOE+00 0.OOE-i00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+0O 0.OOE+O0 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+O0 0.OOE+0O 0.OOE+00 GI-LLI 0.OOE+O0 O.OOE+00 O.OOE+0Q O.OOE+00 0.OOE+00 O.OOE+O0 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+0O 0.OOE+00 0.OOE+O0.0.00E+00 0.OOE+00 0.OOE+O0 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+O0 0.OOE+O0 0.OOE+O0 0.OOE+00 O.OOE-'00 O.OOE+00 0.OOE+00 0.QOE+00 0.OOE+OO 0.OOE+00 0.OOE+0O 0.OOE+0O O.OOE+0O 0.OOE+O0 0.OOE+00 I CPSES -UNITS 1 AND 2- ODCM PART II12-37 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: ADULT PATHWAY: INHALATION NUCLIDE BONE H-3 O.00E+00 C-14 1.82E+04 P-32 1.32E+06 CR-51 0.00E+00 MN-54 0.OOE+00 FE-55 2.46E+04 FE-59 1.18E+04 CO-58 0.00E+00 CO-60 0.00E+00 N 1-63 4.32E+05 ZN-65 3.24E+04 RB-86 0.OOE+00 SR-89 3.04E+05 SR-90 9.92E+07 Y-91 4.62E+05 ZR-95 1.07E+05 NB-95 1.41 E+04 RU-103 1.53E+03 RU-106 6.91E+04 AG-110M 1.08E+04 TE-125M 3.42E+03 TE-1 27M 1.26E+04 TE-129M 9.76E+03 1-131 2.52E+04 1-133 8.64E+03 CS-1 34 3.73E+05 CS-1 36 3.90E+04 CS-1 37 4.78E+05 BA-140 3.90E+04 CE-141 1.99E+04 CE-144 3.43E+06 PR-143 9.36E+03 ND-147 5.27E+03 ORGAN DOSE FACTORS LIVER 1.26E+03 3.41 E+03 7.71 E+04 0.00E+00 3.96E+04 1.70E+04 2.78E+04 1.58E+03 1.15E+04 3.14E+04 1.03E+05 1.35E+05 0.00E+00 0.00E+00 0.00E+00 3.44E+04 7.82E+03 0.00E+00 0.00E+00 1.00E+04 1.58E+03 5.77E+03 4.67E+03 3.58E+04 1.48E+04 8.48E+05 1.46E+05 6.21 E+05 4.90E+01 1.35E+04 1.43E+06 3.75E+03 6.10E+03 T. BODY 1.26E+03 3.41 E+03 5.01 E+04 1.00E+02 6.30E+03 3.94E+03 1.06E+04 2.07E+03 1.48E+04 1.45E+04 4.66E+04 5.90E+04 8.72E+03 6.1OE+06 1.24E+04 2.33E+04 4.21 E+03 6.58E+02 8.72E+03 5.94E+03 4.67E+02 1.57E+03 1.58E+03 2.05E+04 4.52E+03 7.28E+05 1.10E+05 4.28E+05 2.57E+03 1.53E+03 1.84E+05 4.64E+02 3.65E+02 THYROID 1.26E+03 3.41 E+03 0.00E+00 5.95E+01 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 0.OOE+00 0.00E+00 1.05E+03 3.29E+03 3.44E+03 1.19E+07 2.15E+06 O.00E+00 0.00E+00 0.00E+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 KIDNEY 1.26E+03 3.41 E+03 0.OOE+00 2.28E+01 9.84E+03 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 6.90E+04 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 5.42E+04 7.74E+03 5.83E+03 1.34E+05 1.97E+04 1.24E+04 4.58E+04 3.66E+04 6.13E+04 2.58E+04 2.87E+05 8.56E+04 2.22E+05 1.67E+01 6.26E+03 8.48E+05 2.16E+03 3.56E+03 LUNG 1.26E+03 3.41 E+03 0.OOE+00 1.44E+04 1.40E+06 7.21 E+04 1.02E+06 9.28E+05 5.97E+06 1.78E+05 8.64E+05 0.OOE+00 1.40E+06 9.60E+06 1.70E+06 1.77E+06 5.05E+05 5.05E+05 9.36E+06 4.63E+06 3.14E+05 9.60E+05 1.16E+06 0.OOE+00 0.OOE+00 9.76E+04 1.20E+04 7.52E+04 1.27E+06 3.62E+05 7.78E+06 2.81 E+05 2.21 E+05 GI-LLI 1.26E+03 3.41 E+03 8.64E+04 3.32E+03 7.74E+04 6.03E+03 1.88E+05 1.06E+05 2.85E+05 1.34E+04 5.34E+04 1.66E+04 3.50E+05 7.22E+05 3.85E+05 1.50E+05 1.04E+05 1.10E+05 9.12E+05 3.02E+05 7.06E+04 1.50E+05 3.83E+05 6.28E+03 8.88E+03 1.04E+04 1.17E+04 8.40E+03 2.18E+05 1.20E+05 8.16E+05 2.OOE+05 1.73E+05 I CPSES -UNITS 1 AND 2- ODCM PART II12-38 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: TEEN PATHWAY: INHALATION ORGAN DOSE FACTORS NUCLIDE H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-103 RU-106 AG-110M TE-1 25M TE-1 27M TE-1 29M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE O.OOE+00 2.60E+04 1.89E+06 O.OOE+00 O.OOE+00 3.34E+04 1.59E+04 0.OOE+00 0.0OE+00 5.80E+05 3.86E+04 O.OE+00 4.34E+05 1.08E+08 6.61 E+05 1.46E+05 1.86E+04 2.1OE+03 9.84E+04 1.38E+04 4.88E+03 1.80E+04 1.39E+04 3.54E+04 1.22E+04 5.02E+05 5.15E+04 6.70E+05 5.47E+04 2.84E+04 4.89E+06 1.34E+04 7.86E+03 LIVER 1.27E+03 4.87E+03 1.10E+05 0.OOE+00 5.11E+04 2.38E+04 3.70E+04 2.07E+03 1.51 E+04 4.34E+04 1.34E+05 1.90E+05 0.OOE+00 0.OOE+00 0.OOE+00 4.58E+04 1.03E+04 0.OOE+00 O.OOE+00 1.31 E+04 2.24E+03 8.16E+03 6.58E+03 4.91 E+04 2.05E+04 1.13E+06 1.94E+05 8.48E+05 6.70E+01 1.90E+04 2.02E+06 5.31 E+03 8.56E+03 T. BODY 1.27E+03 4.87E+03 7.16E+04 1.32E+02 8.40E+03 5.54E+03 1.43E+04 2.78E+03 1.98E+04 1.98E+04 6.24E+04 8.40E+04 1.25E+04 6.68E+06 1.77E+04 3.15E+04 5.66E+03 8.96E+02 1.24E+04 7.99E+03 6.67E+02 2.18E+03 2.25E+03 2.64E+04 6.22E+03 5.49E+05 1.37E+05 3.11 E+05 3.52E+03 2.17E+03 2.62E+05 6.62E+02 5.13E+02 THYROID 1.27E+03 4.87E+03 O.OOE+00 7.50E+01 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 1.40E+03 4.38E+03 4.58E+03 1.46E+07 2.92E+06 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 KIDNEY 1.27E+03 4.87E+03 0.OOE+00 3.07E+01 1.27E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 8.64E+04 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 6.74E+04 1.OOE+04 7.43E+03 1.90E+05 2.50E+04 0.OOE+00 6.54E+04 5.19E+04 8.40E+04 3.59E+04 3.75E+05 1.10E+05 3.04E+05 2.28E+01 8.88E+03 1.21E+06 3.09E+03 5.02E+03 LUNG 1.27E+03 4.87E+03 0.OOE+00 2.1 OE+04 1.98E+06 1.24E+05 1.53E+06 1.34E+06 8.72E+06 3.07E+05 1.24E+06 0.OOE+00 2.42E+06 1.65E+07 2.94E+06 2.69E+06 7.51 E+05 7.83E+05 1.61 E+07 6.75E+06 5.36E+05 1.66E+06 1.98E+06 0.OOE+00 0.OOE+00 1.46E+05 1.78E+04 1.21 E+05 2.03E+06 6.14E+05 1.34E+07 4.83E+05 3.72E+05 GI-LLI 1.27E+03 4.87E+03 9.28E+04 3.OOE+03 6.68E+04 6.39E+03 1.78E+05 9.52E+04 2.59E+05 1.42E+04 4.66E+04 1.77E+04 3.71 E+05 7.65E+05 4.09E+05 1.49E+05 9.68E+04 1.09E+05 9.60E+05 2.73E+05 7.50E+04 1.59E+05 4.05E+05 6.49E+03 1.03E+04 9.76E+03 1.09E+04 8.48E+03 2.29E+05 1.26E+05 8.64E+05 2.14E+05 1.82E+05 I CPSES -UNITS 1 AND 2- ODCM PART II12-39 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: CHILD PATHWAY: INHALATION ORGAN DOSE FACTORS IKll I'l  H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 N 1-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-1 03 RU-1 06 AG-11iM TE-1 25M TE-1 27M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE O.OOE+00 3.59E+04 2.60E+06 0.OOE+00 O.OOE+00 4.74E+04 2.07E+04 0.OOE+00 0.OOE+00 8.21 E+05 4.26E+04 0.OOE+00 5.99E+05 1.01 E+08 9.14E+05 1.90E+05 2.35E+04 2.79E+03 1.36E+05 1.69E+04 6.73E+03 2.49E+04 1.92E+04 4.81 E+04 1.66E+04 6.51E+05 6.51E+04 9.07E+05 7.40E+04 3.92E+04 6.77E+06 1.85E+04 1.08E+04 LIVER 1.12E+03 6.73E+03 1.14E+05 0.OOE+00 4.29E+04 2.52E+04 3.34E+04 1.77E+03 1.31E+04 4.63E+04 1.13E+05 1.98E+05 0.OOE+00 0.00E+00 0.OOE+00 4.18E+04 9.18E+03 0.00E+00 0.00E+00 1.14E+04 2.33E+03 8.55E+03 6.85E+03 4.81 E+04 2.03E+04 1.01E+06 1.71 E+05 8.25E+05 6.48E+01 1.95E+04 2.12E+06 5.55E+03 8.73E+03 T. BODY 1.12E+03 6.73E+03 9.88E+04 1.54E+02 9.51 E+03 7.77E+03 1.67E+04 3.16E+03 2.26E+04 2.80E+04 7.03E+04 1.14E+05 1.72E+04 6.44E+06 2.44E+04 3.70E+04 6.55E+03 1.07E+03 1.69E+04 9.14E+03 9.14E+02 3.02E+03 3.04E+03 2.73E+04 7.70E+03 2.25E+05 1.16E+05 1.28E+05 4.33E+03 2.90E+03 3.61 E+05 9.14E+02 6.81 E+02 THYROID 1.12E+03 6.73E+03 0.OOE+00 8.55E+01 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.92E+03 6.07E+03 6.33E+03 1.62E+07 3.85E+06 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 KIDNEY 1.12E+03 6.73E+03 0.OOE+00 2.43E+01 1.OOE+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 7.14E+04 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 5.96E+04 8.62E+03 7.03E+03 1.84E+05 2.12E+04 0.OOE+00 6.36E+04 5.03E+04 7.88E+04 3.38E+04 3.30E+05 9.55E+04 2.82E+05 2.11E+01 8.55E+03 1.17E+06 3.OOE+03 4.81E+03 LUNG 1.12E+03 6.73E+03 0.OOE+00 1.70E+04 1.58E+06 1.11E+05 1.27E+06 1.11 E+06 7.07E+06 2.75E+05 9.95E+05 0.OOE+00 2.16E+06 1.48E+07 2.63E+06 2.23E+06 6.14E+05 6.62E+05 1.43E+07 5.48E+06 4.77E+05 1.48E+06 1.76E+06 0.00E+00 0.00E+00 1.21 E+05 1.45E+04 1.04E+05 1.74E+06 5.44E+05 1.20E+07 4.33E+05 3.28E+05 GI-LLI 1.12E+03 6.73E+03 4.22E+04 1.08E+03 2.29E+04 2.87E+03 7.07E+04 3.44E+04 9.62E+04 6.33E+03 1.63E+04 7.99E+03 1.67E+05 3.43E+05 1.84E+05 6.11E+04 3.70E+04 4.48E+04 4.29E+05 1.00E+05 3.38E+04 7.14E+04 1.82E+05 2.84E+03 5.48E+03 3.85E+03 4.18E+03 3.62E+03 1.02E+05 5.66E+04 3.89E+05 9.73E+04 8.21 E+04 I CPSES -UNITS 1 AND 2- ODCM PART II12-40 Rev. 32 TABLE 2.4 PATHWAY DOSE FACTORS AGE GROUP: INFANT PATHWAY: INHALATION ORGAN DOSE FACTORS NUJCIIDF H-3 C-14 P-32 CR-51 MN-54 FE-55 FE-59 CO-58 CO-60 NI-63 ZN-65 RB-86 SR-89 SR-90 Y-91 ZR-95 NB-95 RU-103 RU-106 AG-11 OM TE-1 25M TE-1 27M TE-129M 1-131 1-133 CS-1 34 CS-1 36 CS-1 37 BA-140 CE-141 CE-144 PR-143 ND-147 BONE 0.OOE+00 2.65E+04 2.03E+06 0.OOE+00 O.OOE+00 1.97E+04 1.36E+04 0.OOE+00 0.OOE+00 3.39E+05 1.93E+04 0.OOE+00 3.98E+05 4.09E+07 5.88E+05 1.15E+05 1.57E+04 2.02E+03 8.68E+04 9.98E+03 4.76E+03 1.67E+04 1.41 E+04 3.79E+04 1.32E+04 3.96E+05 4.83E+04 5.49E+05 5.60E+04 2.77E+04 3.19E+06 1.40E+04 7.94E+03 LIVER 6.47E+02 5.31 E+03 1.12E+05 0.OOE+00 2.53E+04 1.17E+04 2.35E+04 1.22E+03 8.02E+03 2.04E+04 6.26E+04 1.90E+05 0.OOE+00 0.OOE+00 0.OOE+00 2.79E+04 6.43E+03 0.OOE+00 0.OOE+00 7.22E+03 1.99E+03 6.90E+03 6.09E+03 4.44E+04 1.92E+04 7.03E+05 1.35E+05 6.12E+05 5.60E+01 1.67E+04 1.21E+06 5.24E+03 8.13E+03 T. BODY 6.47E+02 5.31 E+03 7.74E+04 8.95E+01 4.98E+03 3.33E+03 9.48E+03 1.82E+03 1.18E+04 1.16E+04 3.11 E+04 8.82E+04 1.14E+04 2.59E+06 1.57E+04 2.03E+04 3.78E+03 6.79E+02 1.09E+04 5.OOE+03 6.58E+02 2.07E+03 2.23E+03 1.96E+04 5.60E+03 7.45E+04 5.29E+04 4.55E+04 2.90E+03 1.99E+03 1.76E+05 6.99E+02 5.OOE+02 THYROID 6.47E+02 5.31 E+03 0.OOE+00 5.75E+01 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 0.OOE+00'0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1.62E+03 4.87E+03 5.47E+03 1.48E+07 3.56E+06 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00, 0.OOE+00 0.OOE+00 KIDNEY 6.47E+02 5.31 E+03 0.00E+00 1.32E+01 4.98E+03 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 3.25E+04 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 3.11 E+04 4.72E+03 4.24E+03 1.07E+05 1.09E+04 0.0OE+00 3.75E+04 3.18E+04 5.18E+04 2.24E+04 1.90E+05 5.64E+04 1.72E+05 1.34E+01 5.25E+03 5.38E+05 1.97E+03 3.15E+03 LUNG 6.47E+02 5.31 E+03 0.OOE+00 1.28E+04 1.OOE+06 8.69E+04 1.02E+06 7.77E+05 4.51E+06 2.09E+05 6.47E+05 0.OOE+00 2.03E+06 1.12E+07 2.45E+06 1.75E+06 4.79E+05 5.52E+05 1.16E+07 3.67E+06 4.47E+05 1.31EE+06 1.68E+06 0.OOE+00 0.OOE+00 7.97E+04 1.18E+04 7.13E+04 1.60E+06 5.17E+05 9.84E+06 4.33E+05 3.22E+05 GI-LLI 6.47E+02 5.31 E+03 1.61 E+04 3.57E+02 7.06E+03 1.09E+03 2.48E+04 1.11E+04 3.19E+04 2.42E+03 5.14E+04 3.04E+03 6.40E+04 1.31 E+05 7.03E+04 2.17E+04 1.27E+04 1.61 E+04 1.64E+05 3.30E+04 1.29E+04 2.73E+04 6.90E+04 1.06E+03 2.16E+03 1.33E+03 1.43E+03 1.33E+03 3.84E+04 2.16E+04 1.48E+05 3.72E+04 3.12E+04 CPSES -UNITS 1 AND 2- ODCM PART II12-41 Rev. 32 APPENDIX D (CONTINUED)
The concentration of C-14 in milk is based on the airborne concentration rather than deposition.
Therefore, Rc 0 is based on (X/Q)Rcc,a,o = k' k"' Fm QF UAp DFLc,a,o [0.11/0.16] (p) (f) [Eq. D-3]Where: k' = Units conversion factor pCi/pci (106)k,, = Units conversion factor gm/kg (103)Fm = Stable element transfer coefficient (Table E-1, R.G. 1.109)QF = Cow consumption rate, 50 kg/day (R.G. 1.109)UAP = Receptor's milk consumption rate; 330, 330, 400, 310 liters/yr for infant, child, teenager, and adult age groups, respectively (R.G. 1.109)DFLc,a,o = Ingestion dose conversion factor for C-14, organ o, and age group a, (Tables E-11 to E-14, R.G. 1.109) (mrem/pCi) 0.11 = Fraction of total plant mass consisting of natural carbon (R.G. 1.109)0.16 = Concentration of natural carbon in the atmosphere (gm/m 3) (R.G. 1.109)p = Ratio of the total annual C-14 release time to the total annual time during which photosynthesis occurs. This value is established to be 0.31, based on 70% of C-14 releases being from wGDTs, and 30% of C-14 releases being continuous from the unit vents (ref. IAEA Technical Reports Series. 421,"Management of Waste Containing Tritium and Carbon-14", 2004).f = The fraction of C-14 assumed to be in inorganic form (e.g., C02). Assumed to be 20%. Reference EPRI TR-105715, "Characterization of Carbon-14 Generated by the Nuclear Power Industry", Table 5-1.NOTE: Goat-milk pathway factor, RCc,a,o will be computed using the cow-milk pathway factor equation.
Fm factor for goat-milk will be from Table E-2, R.G. 1.109 QF for goats is 6 kg/day from Table E-3, R.G. 1.109.CPSES -UNITS 1 AND 2- ODCM PART 11 D-3 Rev. 32 APPENDIX E (CONTINUED)
The concentration of C-14 in meat is based on the airborne concentration rather than deposition.
Therefore, RMc is based on (X/Q)RMc,a,o = k' k"' Ff QF UAp DFLc,a,o[0.11/0.16] (p) (f) [Eq. E-3]Where: k' = Units conversion factor pCi/pCi (106)k,,, = Units conversion factor gm/kg (103)Ff = Stable element transfer coefficient (Table E-1, R.G. 1.109)QF = Cow consumption rate, 50 kg/day (R.G. 1.109)UAP = Consumption rate of cow meat for age group a (kg/yr) (R.G. 1.109)DFLc,a,o = Ingestion dose conversion factor for C-14, organ o, and age group a, (Tables E-11 to E-14, R.G. 1.109) (mrem/pCi) 0.11 Fraction of total plant mass consisting of natural carbon (R.G. 1.109)0.16 = Concentration of natural carbon in the atmosphere (gm/mi 3) (R.G. 1.109)p Ratio of the total annual C-14 release time to the total annual time during which photosynthesis occurs. This value is established to be 0.31, based on 70% of C-14 releases being from WGDTs, and 30% of C-14 releases being continuous from the unit vents (ref. IAEA Technical Reports Series. 421,"Management of Waste Containing Tritium and Carbon-14", 2004).f The fraction of C-14 assumed to be in inorganic form (e.g., C02). Assumed to be 20%. Reference EPRI TR-105715, "Characterization of Carbon-14 Generated by the Nuclear Power Industry", Table 5-1.CPSES -UNITS 1 AND 2- ODCM PART 11 E-3 Rev. 32 APPENDIX F (CONTINUED)
The concentration of C-14 in vegetation is based on the airborne concentration rather than deposition.
Therefore, RVi is based on (X/Q)RVc,a,o = k' k"' [ULA fL + USAfg] DFLc,a,o [0.11/0.161 (p) (f) [Eq. F-3]Where: k' = Units conversion factor pCi/pci (106)k- = Units conversion factor gm/kg (103) I jL A = Comsumption rate of fresh leafy vegetation, 0, 26, 42, 64 kg/yr for infant, child, teenage, or adult age groups, respectively (R.G. 1.109)usA =Consumption rate of stored vegetation, 0, 520, 630, 520 kg/yr for infant, child, teenage, or adult age groups, respectively (R.G. 1.109)fL Fraction of the annual intake of fresh leafy vegetation grown locally, 1.0 (NUREG-0133) fg = Fraction of the stored vegetation grown locally .76 (NUREG-0133)
I DFLc,a,o = Ingestion dose conversion factor for C-14, organ o, and age group a, (Tables I E-11 to E-14, R.G. 1.109) (mrem/pCi)
I 0.11 = Fraction of total plant mass consisting of natural carbon (R.G. 1.109)0.16 = Concentration of natural carbon in the atmosphere (gm/m 3) (R.G. 1.109) I p = Ratio of the total annual C-14 release time to the total annual time during which photosynthesis occurs. This value is established to be 0.31, based on 70% of C-14 releases being from WGDTs, and 30% of C-14 releases being continuous from the unit vents (ref. IAEA Technical Reports Series. 421,"Management of Waste Containing Tritium and Carbon-14", 2004).f The fraction of C-14 assumed to be in inorganic form (e.g., C02). Assumed to be 20%. Reference EPRI TR-105715, "Characterization of Carbon-14 Generated by the Nuclear Power Industry", Table 5-1.CPSES -UNITS 1 AND 2- ODCM PARTII1F-2 Rev. 32}}

Revision as of 00:31, 30 April 2019

Redirect to:

Retrieved from "https://kanterella.com/w/index.php?title=ML12128A198&oldid=1551446"